<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40012622</article-id><article-id pub-id-type="pmc">PMC11861496</article-id><article-id pub-id-type="publisher-id">1535621</article-id><article-id pub-id-type="doi">10.3389/fphar.2025.1535621</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>MicroRNAs in atrial fibrillation &#x02013; have we discovered the Holy Grail or opened a Pandora&#x02019;s box?</article-title><alt-title alt-title-type="left-running-head">Balan and Scridon</alt-title><alt-title alt-title-type="right-running-head">
<ext-link xlink:href="https://doi.org/10.3389/fphar.2025.1535621" ext-link-type="uri">10.3389/fphar.2025.1535621</ext-link>
</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Balan</surname><given-names>Alkora Ioana</given-names></name><uri xlink:href="https://loop.frontiersin.org/people/2968144/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Scridon</surname><given-names>Alina</given-names></name><xref rid="c001" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/1065658/overview"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib></contrib-group><aff>
<institution>Physiology Department and Center for Advanced Medical and Pharmaceutical Research</institution>, <institution>Pharmacy, Science and Technology &#x0201c;George Emil Palade&#x0201d; of T&#x000e2;rgu Mure&#x00219;</institution>, <institution>University of Medicine</institution>, <addr-line>T&#x000e2;rgu Mures</addr-line>, <country>Romania</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/605189/overview" ext-link-type="uri">Felix Wiedmann</ext-link>, Heidelberg University Hospital, Germany</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/805882/overview" ext-link-type="uri">Manuel Kraft</ext-link>, Heidelberg University Hospital, Germany</p><p>
<ext-link xlink:href="https://loop.frontiersin.org/people/2394256/overview" ext-link-type="uri">Vitalina Gryshkova</ext-link>, UCB Biopharma SPRL, Belgium</p></fn><corresp id="c001">*Correspondence: Alina Scridon, <email>alinascridon@gmail.com</email>
</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1535621</elocation-id><history><date date-type="received"><day>27</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>24</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Balan and Scridon.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Balan and Scridon</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Atrial fibrillation (AF) causes a heavy socio-economic burden on healthcare systems around the globe. Identification of new preventive, diagnostic, and treatment methods is imperative. In recent years, special attention has been paid to microRNAs (miRNAs) as potential regulators of AF pathogenesis. Through post-transcriptional regulation of genes, miRNAs have been shown to play crucial roles in AF-related structural and electrical atrial remodeling. Altered expression of different miRNAs has been related to proarrhythmic changes in the duration of action potentials and atrial fibrosis. In clinical studies, miRNA changes have been associated with AF, whereas in experimental studies miRNA manipulation has emerged as a potential therapeutic approach. It would appear that, with the advent of miRNAs, we may have found the Holy Grail, and that efficient and personalized AF therapy may be one step away. Yet, the clinical relevance of miRNA evaluation and manipulation remains questionable. Studies have identified numerous miRNAs associated with AF, but none of them have shown sufficient specificity for AF. MicroRNAs are not gene-specific but regulate the expression of a myriad of genes. Cardiac and non-cardiac off-target effects may thus occur following miRNA manipulation. A Pandora&#x02019;s box might thus have opened with the advent of these sophisticated molecules. In this paper, we provide a critical analysis of the clinical and experimental, epidemiological and mechanistic data linking miRNAs to AF, we discuss the most promising miRNA therapeutic approaches, we emphasize a number of questions that remain to be answered, and we identify hotspots for future research.</p></abstract><kwd-group><kwd>antiarrhythmic therapy</kwd><kwd>atrial fibrillation</kwd><kwd>electrical remodeling</kwd><kwd>microRNA</kwd><kwd>structural remodeling</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the University of Medicine, Pharmacy, Science and Technology &#x0201c;George Emil Palade&#x0201d; T&#x000e2;rgu Mure&#x00219; [grant number 171/5/09.01.2024].</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Cardiovascular and Smooth Muscle Pharmacology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>1 Introduction</title><p>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting &#x02248;33 million patients worldwide, and is associated with considerable morbidity, mortality and, quality of life impairment (<xref rid="B29" ref-type="bibr">Kornej et al., 2020</xref>). Numerous risk factors have been associated with the occurrence and progression of AF. Among them, heart failure, diabetes, hypertension, obesity, and structural and ischemic heart disease are strong predictors of AF (<xref rid="B29" ref-type="bibr">Kornej et al., 2020</xref>). Several biomarkers, such as C-reactive protein, cardiac troponins, B-type natriuretic peptide, and components of the renin-angiotensin-aldosterone system (RAAS) have also been associated with AF (<xref rid="B29" ref-type="bibr">Kornej et al., 2020</xref>). However, none of these risk factors or biomarkers have proven enough reliability in predicting future AF and none of them are specific for AF. Multimarker strategies and risk scores have also been proposed as potential approaches for AF prediction. However, none of them have managed to prove their efficacy in clinical trials (<xref rid="B46" ref-type="bibr">Olivia et al., 2019</xref>). Moreover, AF can also occur in individuals devoid of overt risk factors for AF (<xref rid="B46" ref-type="bibr">Olivia et al., 2019</xref>; <xref rid="B18" ref-type="bibr">Fan et al., 2019</xref>).</p><p>MicroRNAs (miRNAs) are short non-coding RNAs that play critical roles in post-transcriptional regulation of gene expression (<xref rid="B72" ref-type="bibr">Yang et al., 2007</xref>; <xref rid="B54" ref-type="bibr">Soeki et al., 2016</xref>; <xref rid="B32" ref-type="bibr">Li et al., 2014</xref>). Several miRNAs have been associated with cardiac pathologies via regulation of genes involved in inflammation, myocardial remodeling, apoptosis, and cardiac ions dynamics (<xref rid="B72" ref-type="bibr">Yang et al., 2007</xref>; <xref rid="B54" ref-type="bibr">Soeki et al., 2016</xref>; <xref rid="B32" ref-type="bibr">Li et al., 2014</xref>). Recent research has demonstrated an association between different cardiac and circulating miRNAs and atrial structural, electrical, and autonomic remodeling, suggesting that they could serve as biomarkers for AF diagnostic and/or prediction, as well as potential therapeutic targets for AF (<xref rid="B72" ref-type="bibr">Yang et al., 2007</xref>; <xref rid="B54" ref-type="bibr">Soeki et al., 2016</xref>; <xref rid="B32" ref-type="bibr">Li et al., 2014</xref>). If confirmed, these hypotheses could radically change the AF landscape. However, none of those miRNAs are specific for AF (<xref rid="B72" ref-type="bibr">Yang et al., 2007</xref>; <xref rid="B54" ref-type="bibr">Soeki et al., 2016</xref>; <xref rid="B32" ref-type="bibr">Li et al., 2014</xref>) and to date, no study has assessed the therapeutic potential of miRNA manipulation for AF in clinical settings.</p><p>This article aims to provide a critical analysis of the most relevant clinical and experimental, epidemiological and mechanistic data linking miRNAs to AF and to discuss the potential role of miRNAs as biomarkers for diagnosis, prognosis and monitoring of AF, as well as therapeutic targets in AF. We also emphasize several questions that remain to be answered and we identify hotspots for future research. To highlight the role of miRNAs in AF, the miRNAs that provide a scientifically comprehensive overview and have practical importance in advancing the management and understanding of AF were selected. miRNAs supported by strong evidence were prioritized, highlighting those extensively documented in both experimental and clinical studies as having significant roles in AF pathophysiology. In addition, the clinical applicability of these miRNAs was considered, focusing on those miRNAs that have demonstrated potential as diagnostic markers, prognostic tools, or therapeutic targets in clinical settings.</p></sec><sec id="s2"><title>2 MicroRNAs in atrial fibrillation</title><p>The pathophysiological basis of AF involves complex mechanisms (<xref rid="F1" ref-type="fig">Figure 1</xref>) (<xref rid="B52" ref-type="bibr">&#x00218;erban et al., 2019</xref>; <xref rid="B51" ref-type="bibr">Scridon et al., 2018</xref>). The biogenesis and mechanism of action of miRNAs (<xref rid="F2" ref-type="fig">Figure 2</xref>) and the potential role of miRNAs as biomarkers and therapeutic targets in cardiovascular diseases have been intensively studied over the past years (<xref rid="B72" ref-type="bibr">Yang et al., 2007</xref>; <xref rid="B54" ref-type="bibr">Soeki et al., 2016</xref>; <xref rid="B32" ref-type="bibr">Li et al., 2014</xref>).</p><fig position="float" id="F1"><label>FIGURE 1</label><caption><p>Relationship between common risk factors, atrial proarrhythmic remodeling, and atrial fibrillation AF, atrial fibrillation.</p></caption><graphic xlink:href="fphar-16-1535621-g001" position="float"/></fig><fig position="float" id="F2"><label>FIGURE 2</label><caption><p>Schematic representation of microRNA biogenesis. Genomic DNA is transcribed into pri-miRNA by RNA polymerase II. Subsequently, endonucleotide cleavage of the pri-miRNA generates a miRNA precursor (pre-miRNA). For intergenic miRNAs, this process is carried out exclusively by ribonuclease 3. For intronic and exonic miRNAs, pre-miRNA formation involves further modulation by splicing enzymes. Pre-miRNA is exported to the cytoplasm. Dicer enzyme processes pre-miRNA and transforms it into duplex miRNA with two arms, of which one will become a mature miRNA and the other will be eliminated.</p></caption><graphic xlink:href="fphar-16-1535621-g002" position="float"/></fig><p>In AF, miRNAs have been associated with changes in the expression of genes involved in cardiac function and atrial tissue remodeling (<xref rid="F3" ref-type="fig">Figure 3</xref>). Experimental and clinical studies identified several miRNAs that are upregulated or downregulated in AF (<xref rid="B72" ref-type="bibr">Yang et al., 2007</xref>; <xref rid="B54" ref-type="bibr">Soeki et al., 2016</xref>; <xref rid="B32" ref-type="bibr">Li et al., 2014</xref>). Changes in miRNA levels were observed not only in the atrial tissue but also in the peripheral blood, offering the possibility of using them as readily available biomarkers for the prediction and/or diagnosis of AF (<xref rid="B72" ref-type="bibr">Yang et al., 2007</xref>; <xref rid="B54" ref-type="bibr">Soeki et al., 2016</xref>; <xref rid="B32" ref-type="bibr">Li et al., 2014</xref>). In addition, the causal link between AF and certain miRNAs suggests that manipulation of miRNA expression could represent a novel therapeutic strategy in AF (<xref rid="B72" ref-type="bibr">Yang et al., 2007</xref>).</p><fig position="float" id="F3"><label>FIGURE 3</label><caption><p>MicroRNAs involved in proarrhythmic atrial electrical and structural remodeling AF, atrial fibrillation; CACNA1C, calcium voltage-gated channel subunit alpha1 C; CACNB1, calcium voltage-gated channel auxiliary subunit beta1; CACNB2, calcium voltage-gated channel auxiliary subunit beta2; COL1A1, collagen type I alpha1 chain; COL3A1, collagen type III alpha1 chain; CTGF, connective tissue growth factor; Cx43, connexin 43; ERK, extracellular regulated mitogen-activated protein kinase; HCN2, 3, hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2, 3; KCNB2, potassium voltage-gated channel subfamily B member 2; KCNE1, potassium voltage-gated channel subfamily E regulatory subunit 1; KCNJ2, potassium inwardly rectifying channel subfamily J member 2; KCNN3, potassium calcium-activated channel subfamily N member 3; SOX6, SRY-box transcription factor 6; TGF-&#x003b2;1, transforming growth factor beta1; TGFR-2, transforming growth factor beta receptor 2.</p></caption><graphic xlink:href="fphar-16-1535621-g003" position="float"/></fig><sec id="s2-1"><title>2.1 MicroRNA-mediated atrial electrical remodeling</title><sec id="s2-1-1"><title>2.1.1 miR-1</title><p>The first studies that demonstrated the role of miR-1 in cardiac electrophysiology were performed in the setting of cardiac ischemia, where miR-1 overexpression was shown to contribute to cardiac arrhythmogenesis (<xref rid="B72" ref-type="bibr">Yang et al., 2007</xref>). In experimental studies, ventricular miR-1 overexpression increased spontaneous Ca2+ release from the sarcoplasmic reticulum, decreased inward Ca2+ current amplitude, and increased RyR2 activity, leading to Ca2+ handling abnormalities, intracellular Ca2+ overload, and arrhythmias (<xref rid="B57" ref-type="bibr">Terentyev et al., 2009</xref>). These changes were accompanied by post-transcriptional repression of KCNJ2 (<xref rid="B72" ref-type="bibr">Yang et al., 2007</xref>). Decreased conductance induced by miR-1 overexpression was attributed to post-transcriptional repression of GJA1, encoding for connexin 43 (Cx43), a key component of gap junctions, which are essential for intercellular conduction in the ventricles (<xref rid="B72" ref-type="bibr">Yang et al., 2007</xref>). Meanwhile, miR-1 knockdown reduced ischemia-induced arrhythmias, suggesting the potential of miR-1 manipulation as antiarrhythmic strategy (<xref rid="B72" ref-type="bibr">Yang et al., 2007</xref>). Considering the importance of Ca2+, GJA1/Cx43, and KCNJ2/Kir2.1/IK1 in atrial electrophysiology, subsequent studies focused on the possible involvement of miR-1 in AF.</p><p>In patients with AF, plasma levels of miR-1 were higher in the left atrium than in the pulmonary veins, suggesting that local left atrial production of miR-1 might be involved in proarrhythmic atrial remodeling (<xref rid="B54" ref-type="bibr">Soeki et al., 2016</xref>). However, the exact changes that occur in miR-1 in AF remain controversial. Left atrial miR-1 levels were significantly higher in patients who developed post-coronary bypass AF than in those who did not, but this was not reflected in the peripheral blood (<xref rid="B60" ref-type="bibr">Tsoporis et al., 2018</xref>). On the contrary, in the study by Girmatsion et al., atrial miR-1 expression was reduced by &#x02248; 86% in patients with persistent AF compared to sinus rhythm controls (<xref rid="B20" ref-type="bibr">Girmatsion et al., 2009</xref>). A progressive decrease in miR-1 expression with advancing age (<xref rid="B33" ref-type="bibr">Li et al., 2015</xref>) may explain at least some of these discrepancies.</p><p>The exact mechanisms by which miR-1 changes lead to atrial electrical remodeling and AF are also incompletely elucidated. In patients with persistent AF, reduced atrial miR-1 levels were associated with an increase in atrial KCNJ2, Kir2.1, and, IK1 density (<xref rid="B20" ref-type="bibr">Girmatsion et al., 2009</xref>). Reduced miR-1 levels were also accompanied by increased HCN2 and HCN4 channels expression in elderly patients with AF (<xref rid="B33" ref-type="bibr">Li et al., 2015</xref>). Although miR-1-dependent gene regulation seems to be involved in Ca2+ homeostasis regulation in the ventricles (<xref rid="B57" ref-type="bibr">Terentyev et al., 2009</xref>), evidence of this regulatory mechanism extending to atrial fibrillation remains unestablished. The potential of miR-1 manipulation as a therapeutic target in AF was tested in a model of programmed atrial electrical stimulation, where right atrial tachypacing led to miR-1 upregulation and KCNE1 and KCNB2 downregulation (<xref rid="B28" ref-type="bibr">Jia et al., 2013</xref>). Contrary to expectations, these were accompanied by an increase in IKs activity and a decrease in atrial efective refractory period (AERP) duration (<xref rid="B28" ref-type="bibr">Jia et al., 2013</xref>). Additional miR-1 upregulation led to further amplification of these molecular and electrical changes. In contrast, administration of locked nucleic acids-based antimiR-1 prolonged the AERP and reduced AF susceptibility and duration in rabbits, supporting the potential role of miR-1 as a therapeutic target in AF (<xref rid="B28" ref-type="bibr">Jia et al., 2013</xref>).</p><p>miR-1 expression is not limited, however, to tissues directly involved in AF, and altered miR-1 expression has also been reported in many other cardiac and non-cardiac diseases (<xref rid="B72" ref-type="bibr">Yang et al., 2007</xref>; <xref rid="B39" ref-type="bibr">Ma et al., 2020</xref>; <xref rid="B15" ref-type="bibr">De Gonzalo-Calvo et al., 2017</xref>; <xref rid="B55" ref-type="bibr">Sugiyama et al., 2020</xref>). Thus, miR-1 manipulation to prevent AF could have off-target effects, whereas the potential use of miR-1 as a biomarker for AF, as proposed in several studies (<xref rid="B72" ref-type="bibr">Yang et al., 2007</xref>; <xref rid="B54" ref-type="bibr">Soeki et al., 2016</xref>), is considerable affected by its low specificity (<xref rid="B32" ref-type="bibr">Li et al., 2014</xref>). In addition, various physiological and pathological conditions make miR-1 expression unstable over time.</p></sec><sec id="s2-1-2"><title>2.1.2 miR-328</title><p>In a study evaluating peripheral, pulmonary vein, and left atrial appendage plasma levels of miR-328 in patients with and without AF, no significant differences were observed in miR-328 plasma levels between patients with AF and those in sinus rhythm. However, intracardiac levels of miR-328 were increased in AF patients compared to their peripheral and pulmonary vein plasma levels, suggesting that altered left atrial miR-328 expression is involved in atrial remodeling (<xref rid="B54" ref-type="bibr">Soeki et al., 2016</xref>). We have recently shown in a rat model of AF a strong association between increased miR-328 levels and AF, suggesting that miR-328 could emerge as a promising biomarker for AF diagnosis (<xref rid="B50" ref-type="bibr">Scridon et al., 2023</xref>). Moreover, in that model, the increase in miR-328 preceded the appearance of the arrhythmia, suggesting that dynamic miR-328 monitoring may predict future AF. Similar associations between increased miR-328 levels and AF were also reported in clinical studies (<xref rid="B24" ref-type="bibr">Huang et al., 2022</xref>).</p><p>Using a computational prediction algorithm, Lu et al. identified CACNA1C and CACNB1, encoding the &#x003b1;1C- and &#x003b2;1-subunits of ICa-L, respectively, as potential targets for miR-328 (<xref rid="B36" ref-type="bibr">Lu et al., 2010</xref>). This was further confirmed by Western blot and luciferase activity assay (<xref rid="B36" ref-type="bibr">Lu et al., 2010</xref>). The authors subsequently demonstrated that miR-328 overexpression increased AF susceptibility in dogs and mice, probably due to decreased ICa-L and AERP shortening (<xref rid="B36" ref-type="bibr">Lu et al., 2010</xref>). Contrarily, antagomiR-328 reversed those changes and decreased AF susceptibility (<xref rid="B36" ref-type="bibr">Lu et al., 2010</xref>).</p><p>However, miR-328 expression is not changed only in AF. Down- or upregulation of miR-328 has been reported in a series of primary tumors and metastases (<xref rid="B65" ref-type="bibr">Wang et al., 2023</xref>). Altering miR-328 levels may thus disrupt other physiological functions and lead to unwanted effects, potentially increasing the risk of neoplasia (<xref rid="B65" ref-type="bibr">Wang et al., 2023</xref>).</p></sec><sec id="s2-1-3"><title>2.1.3 miR-499</title><p>miR-499 was overexpressed in the atrial tissue of patients with AF, compared to patients in sinus rhythm (<xref rid="B34" ref-type="bibr">Ling et al., 2017</xref>). In those patients, miR-499 overexpression was linked to reduced expression of small conductance Ca2+-activated potassium channels (SK3), an association that appears to be attributable to a direct interaction between miR-499 and KCNN3 (<xref rid="B34" ref-type="bibr">Ling et al., 2017</xref>). The expression of the CACNB2-controlled L-type calcium channel &#x003b2;-subunit was reduced in the atria of patients with long-term persistent AF, while inhibition of miR-499a significantly enhanced the expression of CACNB2 in cultured atrial cells (<xref rid="B34" ref-type="bibr">Ling et al., 2017</xref>). In addition, by targeting CACNA1C, miR-499 could modify the expression of the L-type Ca2+ channel Cav1.2 and reduce the activity of ICa-L (<xref rid="B34" ref-type="bibr">Ling et al., 2017</xref>).</p><p>Although miR-499 manipulation emerged as a target for atrial electrical reverse-remodeling, this strategy is far from perfect, since miR-499 is also modified in other pathologies, including systemic lupus erythematosus or stroke (<xref rid="B63" ref-type="bibr">Wang M. et al., 2019</xref>; <xref rid="B27" ref-type="bibr">Jia et al., 2020</xref>; <xref rid="B3" ref-type="bibr">Banach et al., 2017</xref>).</p></sec><sec id="s2-1-4"><title>2.1.4 miR-26</title><p>Reduced atrial expression of miR-26 was highlighted in experimental models and in AF patients (<xref rid="B37" ref-type="bibr">Luo et al., 2013</xref>). Meanwhile, AF ablation seemed to restore miR-26 plasma levels (<xref rid="B13" ref-type="bibr">Dai et al., 2022</xref>). <italic>In vitro</italic> and <italic>in vivo</italic> studies demonstrated miR-26 involvement in regulation of KCNJ2 and, via increased activity of IK1, in action potential duration (APD) shortening (<xref rid="B37" ref-type="bibr">Luo et al., 2013</xref>). miR-26 knockdown increased AF propensity, while miR-26 overexpression reduced AF susceptibility, suggesting a potential therapeutic role for miR-26 manipulation (<xref rid="B37" ref-type="bibr">Luo et al., 2013</xref>).</p><p>Studies have shown that miR-26 is involved in normal tissue growth and development and up- or downregulation of miR-26 was associated with oncogenic or tumor-suppressive genes in various tumor types (<xref rid="B19" ref-type="bibr">Gao and Liu, 2011</xref>). Interventions for miR-26 upregulation to decrease AF susceptibility (<xref rid="B37" ref-type="bibr">Luo et al., 2013</xref>) could increase the risk of glioma (<xref rid="B19" ref-type="bibr">Gao and Liu, 2011</xref>), whereas miR-26 involvement in tissue growth and development may affect its accuracy as stable and specific biomarkers for AF.</p></sec><sec id="s2-1-5"><title>2.1.5 miR-31</title><p>In an experimental model, atrial-specific upregulation of miR-31 led to neuronal nitric oxide synthase (nNOS) depletion via dystrophin translation repression, contributing to APD changes and AF inducibility in mice (<xref rid="B48" ref-type="bibr">Reilly et al., 2016</xref>). In contrast, miR-31 inhibition restored APD and increased dystrophin expression and nNOS content in atrial myocytes from AF patients. In patients with AF, upregulation of miR-31 seemed to be limited to the atrial myocardium (<xref rid="B48" ref-type="bibr">Reilly et al., 2016</xref>). Thus, miR-31 modulation may be a safer approach for AF therapy.</p></sec><sec id="s2-1-6"><title>2.1.6 Other miRNAs</title><p>miR-21 overexpression has been associated with decreased ICa-L activity via decreased expression of CACNA1C and CACNB2 58 (<xref rid="B4" ref-type="bibr">Barana et al., 2014</xref>). Enhanced miR-21 transcription is likely to result from nuclear factor &#x003ba;B pathway activation, which reflects an increased inflammatory status that is commonly seen in AF (<xref rid="B4" ref-type="bibr">Barana et al., 2014</xref>). Recent research has linked low miR-29b levels with decreased Cx43 expression, suggesting that this miRNA may play a role in atrial proarrhythmic electrical remodeling (<xref rid="B38" ref-type="bibr">Lv et al., 2021</xref>). With advancing age, the expression of miR-133 appears to decrease, simultaneously with an increase in HCN2 and HCN4 expression (<xref rid="B33" ref-type="bibr">Li et al., 2015</xref>), which may contribute to an increase in AF susceptibility. Whether these changes are causally linked or represent independent responses to aging and AF remains unclear, highlighting the need for additional studies to elucidate these relationships. Increased miR-155 levels were also seen in the cardiomyocytes of patients with AF, and this was accompanied by a decrease in CACNA1C expression (<xref rid="B62" ref-type="bibr">Wang et al., 2021</xref>). Transfection of miR-155 in human induced pluripotent stem cells-derived atrial cardiomyocytes reduced ICa-L activity, while in mice with miR-155 overexpression APD decreased and there was an increase in AF vulnerability (<xref rid="B62" ref-type="bibr">Wang et al., 2021</xref>). Meanwhile, inhibition of miR-155 reversed the AF phenotype and the related electrical remodeling (<xref rid="B62" ref-type="bibr">Wang et al., 2021</xref>).</p></sec></sec><sec id="s2-2"><title>2.2 MicroRNA-mediated atrial structural remodeling</title><sec id="s2-2-1"><title>2.2.1 miR-21</title><p>miR-21 is expressed in fibroblasts and is involved in cardiac hypertrophy by increasing ERK pathway activity via inhibition of protein sprouty homologue 1 (Spry1) (<xref rid="B58" ref-type="bibr">Thum et al., 2008</xref>). Considering the association between ERK activation and cardiac fibrosis (<xref rid="B58" ref-type="bibr">Thum et al., 2008</xref>), these results suggest that miR-21 could be involved in AF-related structural remodeling. Indeed, studies have shown a 2.5-fold higher left atrial expression of miR-21 in patients with AF compared to sinus rhythm controls (<xref rid="B1" ref-type="bibr">Adam et al., 2012</xref>). However, miR-21 is also expressed in non-atrial tissues and increased miR-21 expression has been observed in several other cardiac and non-cardiac diseases (<xref rid="B5" ref-type="bibr">Bautista-S&#x000e1;nchez et al., 2020</xref>; <xref rid="B71" ref-type="bibr">Yan et al., 2020</xref>; <xref rid="B2" ref-type="bibr">Bai and Bian, 2022</xref>; <xref rid="B35" ref-type="bibr">Liu et al., 2010</xref>).</p><p>The mechanisms by which miR-21 promotes AF are related to both electrical and structural atrial remodeling. Clinical studies demonstrated an association between extensive areas of low voltage in the left atrium of patients with AF and increased expression of miR-21 (<xref rid="B79" ref-type="bibr">Zhou et al., 2018</xref>). Experimental studies in mice with heart failure also associated atrial fibrosis and AF susceptibility with increased miR-21 expression (<xref rid="B9" ref-type="bibr">Cardin et al., 2012</xref>). Increased miR-21 levels were associated with increased amounts of atrial collagen and reduced expression of Spry1, connective tissue growth factor (CTGF), lysyl oxidase, and Rac1-GTPase, all of which have implications in atrial fibrosis (<xref rid="B1" ref-type="bibr">Adam et al., 2012</xref>). miR-21 could also play a role in atrial structural remodeling by activating the PI3K signaling pathway (<xref rid="B76" ref-type="bibr">Zhang et al., 2018</xref>). Meanwhile, miR-21 knockdown prevented left atrial structural remodeling, reduced fibrosis and AF persistence (<xref rid="B9" ref-type="bibr">Cardin et al., 2012</xref>), and doxycycline attenuated atrial remodeling by decreasing miR-21 and modulating miR-21-dependent pathways (<xref rid="B76" ref-type="bibr">Zhang et al., 2018</xref>). However, considering the involvement of miR-21 in many other pathologies, including cancers (<xref rid="B5" ref-type="bibr">Bautista-S&#x000e1;nchez et al., 2020</xref>), its use as a selective therapeutic target is difficult and requires careful study.</p></sec><sec id="s2-2-2"><title>2.2.2 miR-29</title><p>In patients with AF, atrial levels of miR-29b were found to be substantially lower compared to those of patients in sinus rhythm (<xref rid="B14" ref-type="bibr">Dawson et al., 2013</xref>). Unlike other miRNAs, miR-29 exerts antifibrotic effects (<xref rid="B61" ref-type="bibr">Van Rooij et al., 2008</xref>). miR-29 targets multiple extracellular matrix genes, including COL1A1, COL3A1, and fibrillin, and is involved in reducing cardiac (including atrial) fibrosis (<xref rid="B61" ref-type="bibr">Van Rooij et al., 2008</xref>). The decrease in miR-29b expression induced an increase in atrial expression of COL1A1 and in the amount of atrial collagen, confirming the antifibrotic effect of miR-29b (<xref rid="B61" ref-type="bibr">Van Rooij et al., 2008</xref>). In an atrial fibrosis model, administration of angiotensin II increased the amount of fibrotic tissue, reduced the expression of miR-29b, and increased atrial PDGF-B expression, while miR-29b overexpression reduced the degree of fibrosis, probably via miR-29b-mediated PDGF-B expression reduction (<xref rid="B38" ref-type="bibr">Lv et al., 2021</xref>). Another experimental study linked the antifibrotic effect of miR-29b to targeting transforming growth factor-&#x003b2; (TGF-&#x003b2;) receptor type-1 (TGF&#x003b2;R&#x00399;) and inhibiting the Smad-2/3 pathway (<xref rid="B69" ref-type="bibr">Xinyuan et al., 2022</xref>).</p><p>However, miR-29 seems to also play a role in renal and pulmonary fibrosis (<xref rid="B12" ref-type="bibr">Cushing et al., 2011</xref>; <xref rid="B22" ref-type="bibr">Horita et al., 2021</xref>), which may affect its specificity as a biomarker for AF (<xref rid="B12" ref-type="bibr">Cushing et al., 2011</xref>; <xref rid="B22" ref-type="bibr">Horita et al., 2021</xref>; <xref rid="B41" ref-type="bibr">Malpeli et al., 2018</xref>; <xref rid="B70" ref-type="bibr">Xu et al., 2014</xref>). In addition, miR-29 downregulation has been reported in various tumors and autoimmune and hematological disorders (<xref rid="B22" ref-type="bibr">Horita et al., 2021</xref>; <xref rid="B70" ref-type="bibr">Xu et al., 2014</xref>).</p></sec><sec id="s2-2-3"><title>2.2.3 miR-126</title><p>In patients with AF, miR-126 levels were significantly lower than in patients in sinus rhythm (<xref rid="B66" ref-type="bibr">Wei et al., 2015</xref>). miR-126 overexpression has been shown to suppress Spred1 expression, increase ERK activity in primary bone marrow cells, and increase cytokine production (<xref rid="B26" ref-type="bibr">Ishizaki et al., 2011</xref>). However, it remains to be investigated whether these mechanisms are also active at the cardiac level.</p></sec><sec id="s2-2-4"><title>2.2.4 miR-133 and miR-590</title><p>In an AF model based on nicotine administration and rapid pacing, the two interventions induced atrial fibrosis via TGF-&#x003b2;1 and TGF-&#x003b2; receptor type-2 (TGFBR2), in parallel with a significant reduction in the expressions of miR-133 and miR-590, which target TGF-&#x003b2;1 and TGFBR2 (<xref rid="B53" ref-type="bibr">Shan et al., 2009</xref>). Although a direct causal link has not been established, these data suggest that low levels of miR-133 and miR-590 could contribute to atrial fibrosis. In an experimental study in rats with AF (<xref rid="B73" ref-type="bibr">Yao et al., 2020</xref>), suppression of MIAT, an inhibitor of miR133a-3p expression, reduced atrial fibrosis, inhibited the expression of genes that promote collagen deposition, and led to a decrease in CTGF and TGF-&#x003b2;1 levels. These changes were reversed by miR-133a-3p inhibition. However, implementation of such a strategy requires additional safety studies, given that miR-133 also intervenes in other diseases (<xref rid="B23" ref-type="bibr">Hua et al., 2021</xref>).</p></sec><sec id="s2-2-5"><title>2.2.5 miR-30</title><p>In an experimental model of AF in dogs, miR-30 levels were significantly lower 3&#x000a0;weeks after initiation of AF by rapid stimulation of the pulmonary veins (<xref rid="B31" ref-type="bibr">Li et al., 2012</xref>). Although atrial fibrosis was not evaluated in that study, previous studies have shown that miR-30 regulates CTGF, a key profibrotic protein, and controls structural changes in the extracellular matrix of the ventricular myocardium (<xref rid="B31" ref-type="bibr">Li et al., 2012</xref>). In a model of atrial fibrosis induced by angiotensin II, increased expression of the Snail-1 gene was associated with a decrease in miR-30a expression (<xref rid="B16" ref-type="bibr">Duisters et al., 2009</xref>). Meanwhile, an increase in miR-30a levels led to Snail-1 inhibition and decreased periostin expression, suggesting a direct involvement of miR-30a in atrial fibrosis (<xref rid="B74" ref-type="bibr">Yuan et al., 2015</xref>).</p></sec><sec id="s2-2-6"><title>2.2.6 miR-483</title><p>In patients undergoing coronary bypass surgery, preoperative levels of miR-483-5p were significantly higher in patients who developed postoperative AF compared to those who did not, suggesting that miR-483-5p levels may reflect the existence of an arrhythmogenic substrate (<xref rid="B21" ref-type="bibr">Harling et al., 2017</xref>). In studies with experimental pulmonary hypertension, miR-483 had important profibrotic effects (<xref rid="B75" ref-type="bibr">Zhang et al., 2020</xref>). The use of miR-483-5p as a biomarker for postoperative AF has also been proposed (<xref rid="B74" ref-type="bibr">Yuan et al., 2015</xref>). However, the presence of altered miR-483 expression in other pathologies and the ability of miR-483 to self-regulate its expression affects its specificity and sensitivity as an AF biomarker (<xref rid="B75" ref-type="bibr">Zhang et al., 2020</xref>; <xref rid="B42" ref-type="bibr">Matson et al., 2023</xref>).</p></sec><sec id="s2-2-7"><title>2.2.7 miRNA-155 and miRNA-24</title><p>Increased miR-155-5p and miR-24-3p levels were observed in pigs with AF, while ablation reduced the expression of these miRNAs in both pigs and patients with AF (<xref rid="B64" ref-type="bibr">Wang W. et al., 2019</xref>). These post-ablation changes were associated with nitric oxide (NO) reduction, suggesting the involvement of these miRNAs in endothelial NOS signaling pathway regulation (<xref rid="B63" ref-type="bibr">Wang M. et al., 2019</xref>). Unfortunately, neither miR-155 nor miR-24 are specific for AF, as their expression has been reported to be increased or decreased in many other pathologies (<xref rid="B64" ref-type="bibr">Wang W. et al., 2019</xref>).</p></sec><sec id="s2-2-8"><title>2.2.8 Other miRNAs</title><p>Studies have also associated increased miR-328 levels with atrial dilation and with increased left atrial volume index and voltage zone index (<xref rid="B54" ref-type="bibr">Soeki et al., 2016</xref>). Reduced miR-499-5p and increased SOX6 levels were also reported in rats with AF, while miR-499-5p overexpression attenuated atrial fibrosis in that model, probably via SOX6 reduction (<xref rid="B73" ref-type="bibr">Yao et al., 2020</xref>).</p></sec></sec><sec id="s2-3"><title>2.3 MicroRNAs-mediated atrial autonomic remodeling</title><p>The role of miRNAs in autonomic cardiac remodeling has been less studied. However, studies have associated various miRNAs with changes in the autonomic nervous system of the heart. miR-133a has been shown to regulate &#x003b2;1-adrenergic receptor transduction cascade, whereas miR-1/133a clusters regulate adrenergic control of cardiac repolarization (<xref rid="B26" ref-type="bibr">Ishizaki et al., 2011</xref>; <xref rid="B7" ref-type="bibr">Besser et al., 2014</xref>). It remains to be established whether these miRNAs also influence atrial repolarization.</p><p>miR-30 overexpression led to KCNJ3/Kir3.1 downregulation and reduced IK-Ach activity (<xref rid="B44" ref-type="bibr">Morishima et al., 2016</xref>). Since IK-Ach is involved in the regulation of AERP, miR-30 could affect the occurrence of AF (<xref rid="B44" ref-type="bibr">Morishima et al., 2016</xref>). In a canine model, atrial tachypacing increased AF inducibility and mean nerve density in the superior left fat pads. Overexpression of miR-206 additionally increased nerve density, while anti-miR-206 exerted opposite effects (<xref rid="B78" ref-type="bibr">Zhang et al., 2015</xref>). The mechanisms that explain this hyperinnervation are related to an increase of reactive oxygen species, coupled with a decrease in superoxide dismutase 1 induced by miR-206 (<xref rid="B78" ref-type="bibr">Zhang et al., 2015</xref>).</p><p>Recently, bioinformatics analysis of miRNA-predicted target genes suggested that miR-155-5p and miR-302a-3p could regulate nerve growth factor (NGF) signaling (<xref rid="B59" ref-type="bibr">Tran et al., 2019</xref>). The same study demonstrated that the two miRNAs are also associated with left atrial epicardial adipose tissue in AF patients. Given that the epicardial adipose tissue secretes cytokines and growth factors, including NGF, and that NGF can increase the activity of ganglionated plexi, located in the epicardial fat, NGF could represent a link between miR-155-5p and miR-302a-3p and proarrhythmic autonomic remodeling (<xref rid="B59" ref-type="bibr">Tran et al., 2019</xref>).</p></sec><sec id="s2-4"><title>2.4 MicroRNAs as biomarkers in atrial fibrillation</title><p>The onset and progression of AF has been associated with numerous risk factors and with altered levels of several biomarkers. However, none of these risk factors and biomarkers have proven convincing reliability for AF diagnosis or prediction, especially since they are also involved in other cardiac and non-cardiac conditions (<xref rid="B29" ref-type="bibr">Kornej et al., 2020</xref>). Significant efforts have been made to develop risk scores to identify patients prone to AF, but their clinical role is not convincing (<xref rid="B46" ref-type="bibr">Olivia et al., 2019</xref>). The multifactorial etiology and the lack of risk factors for AF in certain patients are likely to contribute to the low reliability of such risk scores (<xref rid="B29" ref-type="bibr">Kornej et al., 2020</xref>; <xref rid="B46" ref-type="bibr">Olivia et al., 2019</xref>; <xref rid="B18" ref-type="bibr">Fan et al., 2019</xref>).</p><p>Accumulating studies have identified numerous miRNAs that are differentially expressed in the cardiac tissue of patients with AF compared to those in sinus rhythm, suggesting that they could be used as diagnostic markers for AF (<xref rid="T1" ref-type="table">Table 1</xref>). Although promising, this strategy involves sampling of the atrial tissue, which is not feasible in most AF patients. Subsequent research has thus focused on identifying miRNAs for which the circulating levels reflect their atrial expression. Due to their ability to associate with various microstructures such as exosomes, microvesicles, and apoptotic bodies, miRNAs exhibit remarkable stability in plasma (<xref rid="B56" ref-type="bibr">Takahashi et al., 2017</xref>). Also, they are often bound to proteins and high-density lipoproteins, which gives them protection against RNase enzymes (<xref rid="B56" ref-type="bibr">Takahashi et al., 2017</xref>). Studies demonstrated modified expression levels of several miRNAs, both in the left atrium and in the peripheral blood of patients with AF compared to those in sinus rhythm (<xref rid="B66" ref-type="bibr">Wei et al., 2015</xref>; <xref rid="B26" ref-type="bibr">Ishizaki et al., 2011</xref>). Plasma levels of miR-29b, miR-21, miR-328, and miR-150 seem to be modified in patients with AF compared to those without AF (<xref rid="B54" ref-type="bibr">Soeki et al., 2016</xref>; <xref rid="B14" ref-type="bibr">Dawson et al., 2013</xref>; <xref rid="B45" ref-type="bibr">Nishi et al., 2013</xref>). In patients with AF, miR-126 serum levels were found to be lower than in the control group (<xref rid="B66" ref-type="bibr">Wei et al., 2015</xref>). However, not all circulating miRNAs reflect their atrial expression. In a study performed in patients with postoperative AF (POAF), although in the atrium there was a difference between miR-208a expression in patients who developed POAF and those who did not, serum levels of miR-208a were not significantly different between the two groups (<xref rid="B21" ref-type="bibr">Harling et al., 2017</xref>). When analyzing the whole blood, among the 385 miRNAs evaluated in patients with AF, only miR-328 remained significantly associated with AF after adjusting for risk factors and RNA concentration and quality (<xref rid="B43" ref-type="bibr">McManus et al., 2014</xref>).</p><table-wrap position="float" id="T1"><label>TABLE 1</label><caption><p>Key microRNAs investigated as biomarkers in atrial fibrillation.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">miRNA</th><th align="center" rowspan="1" colspan="1">Study subjects</th><th align="center" rowspan="1" colspan="1">Stage of disease</th><th align="center" rowspan="1" colspan="1">Sample type</th><th align="center" rowspan="1" colspan="1">Expression change</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1">miR-1</td><td align="center" rowspan="1" colspan="1">Canines</td><td align="center" rowspan="1" colspan="1">Chronic AF</td><td align="center" rowspan="1" colspan="1">Left atrial appendage tissue</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="left" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">Chen et al. (2024)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-1-3p</td><td align="center" rowspan="1" colspan="1">Patients with cryptogenic stroke</td><td align="center" rowspan="1" colspan="1">Subclinical AF</td><td align="center" rowspan="1" colspan="1">Plasma</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="left" rowspan="1" colspan="1">
<xref rid="B6" ref-type="bibr">Benito et al. (2022)</xref>
</td></tr><tr><td rowspan="2" align="center" colspan="1">miR-499</td><td align="center" rowspan="1" colspan="1">Canines</td><td align="center" rowspan="1" colspan="1">Rapid pacing induced chronic AF</td><td align="center" rowspan="1" colspan="1">Left atrial appendage tissue</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="left" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">Chen et al. (2024)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">AF patients</td><td align="center" rowspan="1" colspan="1">Paroxysmal AF</td><td align="center" rowspan="1" colspan="1">Plasma</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="left" rowspan="1" colspan="1">
<xref rid="B40" ref-type="bibr">Ma et al. (2017)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-21</td><td align="center" rowspan="1" colspan="1">AF patients</td><td align="center" rowspan="1" colspan="1">Persistent AF</td><td align="center" rowspan="1" colspan="1">Plasma</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="left" rowspan="1" colspan="1">
<xref rid="B10" ref-type="bibr">Chen et al. (2021)</xref>
</td></tr><tr><td rowspan="2" align="center" colspan="1">miR-328</td><td align="center" rowspan="1" colspan="1">Spontaneously hypertensive rats</td><td align="center" rowspan="1" colspan="1">Paroxysmal AF</td><td align="center" rowspan="1" colspan="1">Left atrium and whole blood</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="left" rowspan="1" colspan="1">
<xref rid="B50" ref-type="bibr">Scridon et al. (2023)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">AF patients</td><td align="center" rowspan="1" colspan="1">Paroxysmal, persistent and permanent AF</td><td align="center" rowspan="1" colspan="1">Whole blood</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="left" rowspan="1" colspan="1">
<xref rid="B43" ref-type="bibr">McManus et al. (2014)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-483</td><td align="center" rowspan="1" colspan="1">AF patients</td><td align="center" rowspan="1" colspan="1">Post-operative AF</td><td align="center" rowspan="1" colspan="1">Serum</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="left" rowspan="1" colspan="1">
<xref rid="B21" ref-type="bibr">Harling et al. (2017)</xref>
</td></tr><tr><td rowspan="3" align="center" colspan="1">miR-29b</td><td align="center" rowspan="1" colspan="1">Dogs</td><td align="center" rowspan="1" colspan="1">Congestive heart failure -related AF</td><td align="center" rowspan="1" colspan="1">Atrial tissue</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="left" rowspan="1" colspan="1">
<xref rid="B14" ref-type="bibr">Dawson et al. (2013)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">AF and chronic heart failure patients</td><td align="center" rowspan="1" colspan="1">Persistent AF</td><td align="center" rowspan="1" colspan="1">Plasma</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="left" rowspan="1" colspan="1">
<xref rid="B14" ref-type="bibr">Dawson et al. (2013)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">AF patients</td><td align="center" rowspan="1" colspan="1">Persistent AF</td><td align="center" rowspan="1" colspan="1">Atrial tissue</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="left" rowspan="1" colspan="1">
<xref rid="B14" ref-type="bibr">Dawson et al. (2013)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-30</td><td align="center" rowspan="1" colspan="1">Canines</td><td align="center" rowspan="1" colspan="1">Rapid pacing induced sustained AF</td><td align="center" rowspan="1" colspan="1">Atrial tissue</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="left" rowspan="1" colspan="1">
<xref rid="B31" ref-type="bibr">Li et al. (2012)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-133</td><td align="center" rowspan="1" colspan="1">Canines</td><td align="center" rowspan="1" colspan="1">Rapid pacing induced sustained AF</td><td align="center" rowspan="1" colspan="1">Atrial tissue</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="left" rowspan="1" colspan="1">
<xref rid="B31" ref-type="bibr">Li et al. (2012)</xref>
</td></tr><tr><td rowspan="2" align="center" colspan="1">miR-208b</td><td align="center" rowspan="1" colspan="1">AF patients</td><td align="center" rowspan="1" colspan="1">Paroxysmal and persistent AF</td><td align="center" rowspan="1" colspan="1">Serum</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="left" rowspan="1" colspan="1">
<xref rid="B47" ref-type="bibr">Paul et al. (2021)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Myocytes isolated from AF patients</td><td align="center" rowspan="1" colspan="1">Chronic AF</td><td align="center" rowspan="1" colspan="1">Atrial myocytes</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="left" rowspan="1" colspan="1">
<xref rid="B8" ref-type="bibr">Ca&#x000f1;&#x000f3;n et al. (2016)</xref>
</td></tr></tbody></table><table-wrap-foot><fn><p>AF, atrial fibrillation.</p></fn></table-wrap-foot></table-wrap><p>Studies, including from our team, demonstrated that atrial remodeling precedes the occurrence of AF (<xref rid="B52" ref-type="bibr">&#x00218;erban et al., 2019</xref>). Considering that several miRNAs have been associated with atrial remodeling, evaluating these miRNAs at an early stage could help identify patients predisposed to AF. In patients undergoing coronary bypass grafting, miR-483-5p atrial expression level was higher in patients who developed POAF than in those who did not. More importantly, the peripheral level of miR-483-5p was also significantly higher in POAF compared to control patients even before surgery (<xref rid="B21" ref-type="bibr">Harling et al., 2017</xref>). In a rat model of AF, we have also shown that changes in miR-328 expression preceded the occurrence of AF (<xref rid="B50" ref-type="bibr">Scridon et al., 2023</xref>). These results suggest that dynamic changes in peripheral miR-483-5p and/or miR-328 levels could emerge as biomarkers for AF prediction. Unfortunately, none of these miRNAs are specific for AF (<xref rid="B65" ref-type="bibr">Wang et al., 2023</xref>; <xref rid="B42" ref-type="bibr">Matson et al., 2023</xref>).</p><p>The potential role of miRNAs as biomarkers of AF recurrence after cardioversion or catheter ablation has also been investigated. miR-21 serum levels negatively correlated with ablation success at 1-year follow-up, suggesting that miR-21 levels could stratify patients according to the risk of recurrence and help plan more extensive ablative treatment in patients at high risk of recurrence (<xref rid="B79" ref-type="bibr">Zhou et al., 2018</xref>). miR-155 levels measured post-cardioversion also proved useful for AF recurrence risk evaluation (<xref rid="B77" ref-type="bibr">Zhang et al., 2019</xref>).</p><p>Also, miR-22-3p and miR-107 levels were significantly higher and miR-146a-5p levels were significantly lower in patients with AF who had an increased risk of major adverse cardiovascular events (<xref rid="B49" ref-type="bibr">Rivera-Caravaca et al., 2020</xref>). Adding these miRNAs to the 2MACE score increased its predictive ability in AF patients (<xref rid="B49" ref-type="bibr">Rivera-Caravaca et al., 2020</xref>). Although these hypotheses need further confirmation from larger-scale studies, they can be a starting point for establishing miRNAs as biomarkers for major cardiovascular events in patients with AF. Many other miRNAs have or are currently being studied in the context of FA, indicating a rapidly expanding field that holds significant promise for the discovery of new biomarkers.</p></sec><sec id="s2-5"><title>2.5 MicroRNAs as therapeutic targets in atrial fibrillation</title><p>Studies have demonstrated that changes in miRNA expression can induce a substrate that promotes AF onset and/or maintenance, while restoring normal miRNA expression can reduce AF risk (<xref rid="T2" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="T2"><label>TABLE 2</label><caption><p>Effects of <italic>in vivo</italic> manipulation of microRNAs associated with atrial fibrillation.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">miRNA</th><th align="center" rowspan="1" colspan="1">Species</th><th align="center" rowspan="1" colspan="1">miRNA manipulation</th><th align="center" rowspan="1" colspan="1">Effect</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td rowspan="2" align="center" colspan="1">miR-1</td><td align="center" rowspan="1" colspan="1">Rabbit</td><td align="center" rowspan="1" colspan="1">Overexpression: lentivirus construct containing miR-1 precursor sequence</td><td align="center" rowspan="1" colspan="1">KCNE1, KCNB2 downregulation, AERP shortening, increased <italic>I</italic>
<sub>Ks</sub> activity, increased AF inducibility</td><td align="center" rowspan="1" colspan="1">
<xref rid="B28" ref-type="bibr">Jia et al. (2013)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Rabbit</td><td align="center" rowspan="1" colspan="1">Knockdown: lentivirus construct containing anti-miR-1 oligonucleotide</td><td align="center" rowspan="1" colspan="1">Alleviated KCNE1 and KCNB2 downregulation and AERP shortening, increased <italic>I</italic>
<sub>Ks</sub> activity</td><td align="center" rowspan="1" colspan="1">
<xref rid="B28" ref-type="bibr">Jia et al. (2013)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-21</td><td align="center" rowspan="1" colspan="1">Rat</td><td align="center" rowspan="1" colspan="1">Knockdown: miR-21 antagomiR</td><td align="center" rowspan="1" colspan="1">Reduced atrial fibrosis and AF</td><td align="center" rowspan="1" colspan="1">
<xref rid="B9" ref-type="bibr">Cardin et al. (2012)</xref>
</td></tr><tr><td rowspan="2" align="center" colspan="1">miR-26</td><td align="center" rowspan="1" colspan="1">Mouse</td><td align="center" rowspan="1" colspan="1">Overexpression: adeno-associated virus containing miR-26a mimic</td><td align="center" rowspan="1" colspan="1">KCNJ2/Kir2.1 expression suppression, reduced AF</td><td align="center" rowspan="1" colspan="1">
<xref rid="B37" ref-type="bibr">Luo et al. (2013)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Mouse</td><td align="center" rowspan="1" colspan="1">Knockdown: adeno-associated virus containing antimiR-26a sequence</td><td align="center" rowspan="1" colspan="1">Increased KCNJ2/Kir2.1 expression, increased AF</td><td align="center" rowspan="1" colspan="1">
<xref rid="B37" ref-type="bibr">Luo et al. (2013)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-29b</td><td align="center" rowspan="1" colspan="1">Mouse</td><td align="center" rowspan="1" colspan="1">Knockdown: adeno-associated virus containing antimiR-29b sponge</td><td align="center" rowspan="1" colspan="1">Increased atrial COL1A1 and collagen content</td><td align="center" rowspan="1" colspan="1">
<xref rid="B14" ref-type="bibr">Dawson et al. (2013)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-328</td><td align="center" rowspan="1" colspan="1">Dog</td><td align="center" rowspan="1" colspan="1">Overexpression: adenovirus infection containing miR-328 precursor</td><td align="center" rowspan="1" colspan="1">Diminished L-type Ca<sup>2+</sup> current activity, shortened atrial APD, enhanced AF</td><td align="center" rowspan="1" colspan="1">
<xref rid="B36" ref-type="bibr">Lu et al. (2010)</xref>
</td></tr></tbody></table><table-wrap-foot><fn><p>AERP, atrial effective refractory period; AF, atrial fibrillation; APD, action potential duration.</p></fn></table-wrap-foot></table-wrap><p>Decreased expression of miRNAs associated with AF can be addressed using synthetic miRNA duplex approaches (miRNA mimics) or virus-mediated miRNA transfer (<xref rid="B25" ref-type="bibr">Ishida and Selaru, 2013</xref>). miRNA mimics have been used in experimental studies to evaluate the impact of miR-9, miR-23a, and miR-34a overexpression on the mechanisms involved in AF, but the vast majority have not been yet tested <italic>in vivo</italic> (<xref rid="B67" ref-type="bibr">Wiedmann et al., 2022</xref>). Importantly, <italic>in vivo</italic> studies that have used this strategy for other pathologies have not reported significant adverse reactions (<xref rid="B30" ref-type="bibr">Lhamyani et al., 2021</xref>). Lentivirus and adenovirus transfection containing precursors of miR-1 and miR-328 were used to increase the expression of these miRNAs, while an adeno-associated virus containing miR-26a mimic was used to increase the expression of miR-26a (<xref rid="T2" ref-type="table">Table 2</xref>) (<xref rid="B28" ref-type="bibr">Jia et al., 2013</xref>; <xref rid="B36" ref-type="bibr">Lu et al., 2010</xref>; <xref rid="B37" ref-type="bibr">Luo et al., 2013</xref>). Although the use of cardiotropic adeno-associated virus-mediated transfer seems safe in terms of extracardiac effects, unwanted immune or inflammatory responses and relatively low load capacity remain the main disadvantages of this method (<xref rid="B14" ref-type="bibr">Dawson et al., 2013</xref>; <xref rid="B25" ref-type="bibr">Ishida and Selaru, 2013</xref>).</p><p>For miRNAs with increased levels involved in AF, studies used three strategies to decrease miRNA levels: antimiRs, miRNA sponges, and miRNA erasers (<xref rid="B25" ref-type="bibr">Ishida and Selaru, 2013</xref>). Numerous studies have demonstrated the therapeutic potential of antimiRs in AF (<xref rid="T2" ref-type="table">Table 2</xref>), without major adverse reactions (<xref rid="B28" ref-type="bibr">Jia et al., 2013</xref>; <xref rid="B36" ref-type="bibr">Lu et al., 2010</xref>; <xref rid="B9" ref-type="bibr">Cardin et al., 2012</xref>). However, considering the systemic delivery, antimiRs could have extracardiac adverse effects (<xref rid="B25" ref-type="bibr">Ishida and Selaru, 2013</xref>). miRNA sponges and miRNA erasers seem to be safer from this point of view. In AF, decreasing the expression of miR-29b and miR-378 using a sponge-based strategy had no adverse reactions (<xref rid="B14" ref-type="bibr">Dawson et al., 2013</xref>; <xref rid="B68" ref-type="bibr">Wu et al., 2023</xref>). However, controlling the administered dose for successfully inhibiting the miRNA of interest is challenging (<xref rid="B17" ref-type="bibr">Ebert and Sharp, 2010</xref>). A much more specific approach involves the use of single-stranded masking oligonucleotides (miR-masks) (<xref rid="B25" ref-type="bibr">Ishida and Selaru, 2013</xref>). The advantage is that a specific mRNA target is blocked, while the other miRNA targets are not affected. miR-masks were used to study the effect of miR-26 on KCNJ2/KIR2.1 expression in AF, without adverse effects (<xref rid="B37" ref-type="bibr">Luo et al., 2013</xref>).</p><p>Experimental studies have shown a potential therapeutic role for miRNA-based approaches in AF. However, their long-term efficacy, safety, and pharmacokinetics in humans remain unknown. Future studies will have to elucidate if the results observed in experimental studies are also applicable in humans and if these approaches are sufficiently safe for clinical use.</p></sec></sec><sec id="s3"><title>3 Gaps in knowledge and future research</title><p>Identification of reliable AF diagnostic and predictive biomarkers is an area of ongoing research. The diagnosis of AF is established based on the identification of a typical arrhythmic episode on an ECG tracing. However, AF is often intermittent and asymptomatic. Hence, it often escapes detection, exposing patients to increased risk of complications. Readily available diagnostic AF biomarkers could identify patients in whom AF (ECG-based) diagnostic strategies should be intensified. This would be of particular interest in patients at risk of stroke, in whom AF diagnosis will be followed by prophylactic anticoagulation. In parallel, a reliable AF predictive biomarker could guide AF screening strategies and intensify substrate-modifying approaches to reduce AF. Such biomarkers could also guide antiarrhythmic therapies and improve selection for catheter ablation, reducing the rates of complications and costs. miRNAs are seen as highly promising in these regards, and several miRNAs have been associated with the presence and recurrence of AF. However, to date, with the exception of miR-31, no miRNA has been identified as being specific for AF, and the predictive ability of miRNAs identified so far is rather modest. More will have to be done to identify miRNAs specific for AF and validate them as AF biomarkers. Maybe the solution will come from a combination of multiple miRNAs with or without protein biomarkers on the same panel. Given the complexity of AF, such a tool would provide a more comprehensive picture of AF and could improve diagnostic accuracy.</p><p>Currently available antiarrhythmic drugs have limited efficacy and high side-effect profiles. Although promising in the preclinical studies, most upstream therapies have failed to show similar success in the clinical trials. Given their contribution to AF pathogenesis, miRNAs could represent the key to a novel therapeutic approach. Experimental studies are again very promising in this regard, although no clinical data is available at this point. Given the complexity and the multitude of mechanisms in which miRNAs are involved, miRNA manipulation could influence several pathophysiological pathways involved in AF, which places them as potential multifunctional therapeutic strategies in AF. However, the same features of miRNAs raise concerns regarding the potential off-target effects of miRNA manipulation, which could affect cardiac regions other than the atria or even organs other than the heart. For instance, miR-328 levels were significantly higher in animals with AF than in those without (<xref rid="B50" ref-type="bibr">Scridon et al., 2023</xref>), suggesting that miR-328 could represent a possible target for AF therapy. miR-328 is, however, a known tumor suppressor, and decreased miR-328 levels have been reported in several types of cancers, precluding its inhibition as a potential therapeutic approach for AF. Similar features are also seen for other miRNAs associated with AF. Strategies designed to specifically target atrial miRNA expression will probably provide the solution, but technical challenges remain to be overcome.</p><p>With the advent of miRNAs, we may have discovered the Holy Grail. However, extensive investigations and additional research are still needed before miRNAs become therapeutic targets or biomarkers in AF. Collaboration between multidisciplinary teams that include academic researchers, clinicians, biotechnologists and pharmaceutical companies is essential for the discovery of the specific miRNA or a panel of miRNAs with potential clinical utility. Performing more robust preclinical studies that use sensitive and specific miRNA detection methods are imperative. Many studies have used microarray techniques, which is a semi-quantitative method with high rates of false negative and positive results. The use of quantitative methods (e.g., qRT-PCR) could improve our knowledge about miRNA involvement in AF. The limitations of the clinical studies performed so far cannot be overlooked. The small number of patients and the high inter-individual variability in terms of sex, age, drug therapies, and concomitant conditions contribute to the inconsistencies of the results. Large multi-center datasets and registries will be needed to identify AF-specific miRNAs that could be used for AF prediction, diagnosis, and therapy, if such miRNAs exist. Last but not least, the great efforts of consortia are crucial for the standardization of experimental protocols. They ensure the experimental protocols reproducibility and the miRNAs validation in extended cohorts of patients, thus accelerating the use of miRNAs in clinical practice. The demonstrated success of other miRNAs that have proven effective in the treatment of other diseases such as cancer offer hope for similar achievements in AF, emphasizing the importance of comprehensive preclinical studies followed by rigorous clinical trials.</p></sec><sec sec-type="conclusion" id="s4"><title>4 Conclusion</title><p>MicroRNAs play an essential role in regulating structural, electrical, and autonomic remodeling in AF. Experimental studies have shown that miRNA manipulation could prevent or even reverse pathological remodeling in AF. Clinical and preclinical studies suggest that changes in miRNA levels in blood or atrial tissue could emerge as novel biomarkers for the diagnosis and/or prediction of AF. However, it remains to be determined if and which of the miRNAs associated with AF have sufficient specificity and sensitivity to be used as AF biomarkers in clinical practice. Further research is also needed to establish if therapeutic strategies based on miRNA manipulation could emerge as effective and safe approaches for patients with AF.</p></sec></body><back><sec sec-type="author-contributions" id="s5"><title>Author contributions</title><p>AB: Writing&#x02013;original draft. AS: Writing&#x02013;review and editing.</p></sec><sec sec-type="COI-statement" id="s7"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s8"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s9"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adam</surname><given-names>O.</given-names></name><name><surname>L&#x000f6;hfelm</surname><given-names>B.</given-names></name><name><surname>Thum</surname><given-names>T.</given-names></name><name><surname>Gupta</surname><given-names>S. K.</given-names></name><name><surname>Puhl</surname><given-names>S. L.</given-names></name><name><surname>Sch&#x000e4;fers</surname><given-names>H. J.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Role of miR-21 in the pathogenesis of atrial fibrosis</article-title>. <source>Basic Res. Cardiol.</source>
<volume>107</volume>, <fpage>278</fpage>. <pub-id pub-id-type="doi">10.1007/s00395-012-0278-0</pub-id>
<pub-id pub-id-type="pmid">22760500</pub-id>
</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bai</surname><given-names>X.</given-names></name><name><surname>Bian</surname><given-names>Z.</given-names></name></person-group> (<year>2022</year>). <article-title>MicroRNA-21 is a versatile regulator and potential treatment target in central nervous system disorders</article-title>. <source>Front. Mol. Neurosci.</source>
<volume>15</volume>, <fpage>842288</fpage>&#x02013;<lpage>842313</lpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2022.842288</pub-id>
<pub-id pub-id-type="pmid">35173580</pub-id>
</mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Banach</surname><given-names>E.</given-names></name><name><surname>Dmitrzak-Weglarz</surname><given-names>M.</given-names></name><name><surname>Pawlak</surname><given-names>J.</given-names></name><name><surname>Kapelski</surname><given-names>P.</given-names></name><name><surname>Szczepankiewicz</surname><given-names>A.</given-names></name><name><surname>Rajewska-Rager</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Dysregulation of miR-499, miR-708 and miR-1908 during a depression episode in bipolar disorders</article-title>. <source>Neurosci. Lett.</source>
<volume>654</volume>, <fpage>117</fpage>&#x02013;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2017.06.019</pub-id>
<pub-id pub-id-type="pmid">28647289</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barana</surname><given-names>A.</given-names></name><name><surname>Matamoros</surname><given-names>M.</given-names></name><name><surname>Dolz-Gait&#x000f3;n</surname><given-names>P.</given-names></name><name><surname>P&#x000e9;rez-Hern&#x000e1;ndez</surname><given-names>M.</given-names></name><name><surname>Amor&#x000f3;s</surname><given-names>I.</given-names></name><name><surname>N&#x000fa;&#x000f1;ez</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Chronic atrial fibrillation increases microRNA-21 in human atrial myocytes decreasing L-type calcium current</article-title>. <source>Arrhythmia Electrophysiol.</source>
<volume>7</volume>, <fpage>861</fpage>&#x02013;<lpage>868</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCEP.114.001709</pub-id>
</mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bautista-S&#x000e1;nchez</surname><given-names>D.</given-names></name><name><surname>Arriaga-Canon</surname><given-names>C.</given-names></name><name><surname>Pedroza-Torres</surname><given-names>A.</given-names></name><name><surname>De La Rosa-Vel&#x000e1;zquez</surname><given-names>I. A.</given-names></name><name><surname>Gonz&#x000e1;lez-Barrios</surname><given-names>R.</given-names></name><name><surname>Contreras-Espinosa</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics</article-title>. <source>Mol. Ther. Nucleic Acids</source>
<volume>20</volume>, <fpage>409</fpage>&#x02013;<lpage>420</lpage>. <pub-id pub-id-type="doi">10.1016/j.omtn.2020.03.003</pub-id>
<pub-id pub-id-type="pmid">32244168</pub-id>
</mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benito</surname><given-names>B.</given-names></name><name><surname>Garc&#x000ed;a-El&#x000ed;as</surname><given-names>A.</given-names></name><name><surname>Ois</surname><given-names>&#x000c1;.</given-names></name><name><surname>Tajes</surname><given-names>M.</given-names></name><name><surname>Vall&#x000e8;s</surname><given-names>E.</given-names></name><name><surname>Ble</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Plasma levels of miRNA-1-3p are associated with subclinical atrial fibrillation in patients with cryptogenic stroke</article-title>. <source>Rev. Esp. Cardiol. Engl. Ed.</source>
<volume>75</volume>, <fpage>717</fpage>&#x02013;<lpage>726</lpage>. <pub-id pub-id-type="doi">10.1016/j.rec.2021.12.001</pub-id>
<pub-id pub-id-type="pmid">35067470</pub-id>
</mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Besser</surname><given-names>J.</given-names></name><name><surname>Malan</surname><given-names>D.</given-names></name><name><surname>Wystub</surname><given-names>K.</given-names></name><name><surname>Bachmann</surname><given-names>A.</given-names></name><name><surname>Wietelmann</surname><given-names>A.</given-names></name><name><surname>Sasse</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>MiRNA-1/133a clusters regulate adrenergic control of cardiac repolarization</article-title>. <source>PLoS One</source>
<volume>9</volume>, <fpage>e113449</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0113449</pub-id>
<pub-id pub-id-type="pmid">25415383</pub-id>
</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ca&#x000f1;&#x000f3;n</surname><given-names>S.</given-names></name><name><surname>Caballero</surname><given-names>R.</given-names></name><name><surname>Herraiz-Mart&#x000ed;nez</surname><given-names>A.</given-names></name><name><surname>P&#x000e9;rez-Hern&#x000e1;ndez</surname><given-names>M.</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>B.</given-names></name><name><surname>Atienza</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>miR-208b upregulation interferes with calcium handling in HL-1 atrial myocytes: implications in human chronic atrial fibrillation</article-title>. <source>J. Mol. Cell. Cardiol.</source>
<volume>99</volume>, <fpage>162</fpage>&#x02013;<lpage>173</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2016.08.012</pub-id>
<pub-id pub-id-type="pmid">27545043</pub-id>
</mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cardin</surname><given-names>S.</given-names></name><name><surname>Guasch</surname><given-names>E.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Naud</surname><given-names>P.</given-names></name><name><surname>Quang</surname><given-names>K.Le</given-names></name><name><surname>Shi</surname><given-names>Y. F.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure</article-title>. <source>Circ. Arrhythmia Electrophysiol.</source>
<volume>5</volume>, <fpage>1027</fpage>&#x02013;<lpage>1035</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCEP.112.973214</pub-id>
</mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>Y. L.</given-names></name><name><surname>Yang</surname><given-names>X. C.</given-names></name></person-group> (<year>2021</year>). <article-title>Relationship between circulating miRNA-21, atrial fibrosis, and atrial fibrillation in patients with atrial enlargement</article-title>. <source>Ann. Palliat. Med.</source>
<volume>10</volume>, <fpage>12742</fpage>&#x02013;<lpage>12749</lpage>. <pub-id pub-id-type="doi">10.21037/apm-21-3518</pub-id>
<pub-id pub-id-type="pmid">35016439</pub-id>
</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Meng</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Identification of miR-1 and miR-499 in chronic atrial fibrillation by bioinformatics analysis and experimental validation</article-title>. <source>Front. Cardiovasc. Med.</source>
<volume>11</volume>, <fpage>1400643</fpage>. <pub-id pub-id-type="doi">10.3389/fcvm.2024.1400643</pub-id>
<pub-id pub-id-type="pmid">39221422</pub-id>
</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cushing</surname><given-names>L.</given-names></name><name><surname>Kuang</surname><given-names>P. P.</given-names></name><name><surname>Qian</surname><given-names>J.</given-names></name><name><surname>Shao</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Little</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>miR-29 is a major regulator of genes associated with pulmonary fibrosis</article-title>. <source>Am. J. Respir. Cell. Mol. Biol.</source>
<volume>45</volume>, <fpage>287</fpage>&#x02013;<lpage>294</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2010-0323OC</pub-id>
<pub-id pub-id-type="pmid">20971881</pub-id>
</mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dai</surname><given-names>M.</given-names></name><name><surname>Jiang</surname><given-names>T.</given-names></name><name><surname>Luo</surname><given-names>C.</given-names></name><name><surname>dong</surname><given-names>D. W.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>yan</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Radiofrequency ablation reduces expression of SELF by upregulating the expression of microRNA-26a/b in the treatment of atrial fibrillation</article-title>. <source>J. Interv. Card. Electrophysiol.</source>
<volume>65</volume>, <fpage>663</fpage>&#x02013;<lpage>673</lpage>. <pub-id pub-id-type="doi">10.1007/s10840-022-01305-x</pub-id>
<pub-id pub-id-type="pmid">35864328</pub-id>
</mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dawson</surname><given-names>K.</given-names></name><name><surname>Wakili</surname><given-names>R.</given-names></name><name><surname>&#x000d6;rd&#x000f6;g</surname><given-names>B.</given-names></name><name><surname>Clauss</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Iwasaki</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation</article-title>. <source>Circulation</source>
<volume>127</volume>, <fpage>1466</fpage>&#x02013;<lpage>1475</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.001207</pub-id>
<pub-id pub-id-type="pmid">23459615</pub-id>
</mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Gonzalo-Calvo</surname><given-names>D.</given-names></name><name><surname>Van Der Meer</surname><given-names>R. W.</given-names></name><name><surname>Rijzewijk</surname><given-names>L. J.</given-names></name><name><surname>Smit</surname><given-names>J. W. A.</given-names></name><name><surname>Revuelta-Lopez</surname><given-names>E.</given-names></name><name><surname>Nasarre</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes</article-title>. <source>Sci. Rep.</source>
<volume>7</volume>, <fpage>1</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-00070-6</pub-id>
<pub-id pub-id-type="pmid">28127051</pub-id>
</mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duisters</surname><given-names>R. F.</given-names></name><name><surname>Tijsen</surname><given-names>A. J.</given-names></name><name><surname>Schroen</surname><given-names>B.</given-names></name><name><surname>Leenders</surname><given-names>J. J.</given-names></name><name><surname>Lentink</surname><given-names>V.</given-names></name><name><surname>Van Der Made</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>MiR-133 and miR-30 Regulate connective tissue growth factor: implications for a role of micrornas in myocardial matrix remodeling</article-title>. <source>Circ. Res.</source>
<volume>104</volume>, <fpage>170</fpage>&#x02013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.182535</pub-id>
<pub-id pub-id-type="pmid">19096030</pub-id>
</mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ebert</surname><given-names>M. S.</given-names></name><name><surname>Sharp</surname><given-names>P. A.</given-names></name></person-group> (<year>2010</year>). <article-title>MicroRNA sponges: progress and possibilities</article-title>. <source>Rna</source>
<volume>16</volume>, <fpage>2043</fpage>&#x02013;<lpage>2050</lpage>. <pub-id pub-id-type="doi">10.1261/rna.2414110</pub-id>
<pub-id pub-id-type="pmid">20855538</pub-id>
</mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fan</surname><given-names>S. M.</given-names></name><name><surname>Fann</surname><given-names>A.</given-names></name><name><surname>Nah</surname><given-names>G.</given-names></name><name><surname>Pletcher</surname><given-names>M. J.</given-names></name><name><surname>Olgin</surname><given-names>J. E.</given-names></name><name><surname>Marcus</surname><given-names>G. M.</given-names></name></person-group> (<year>2019</year>). <article-title>Characteristics of atrial fibrillation patients with a family history of atrial fibrillation</article-title>. <source>J. Atr. Fibrillation</source>
<volume>12</volume>, <fpage>2198</fpage>&#x02013;<lpage>2207</lpage>. <pub-id pub-id-type="doi">10.4022/jafib.2198</pub-id>
<pub-id pub-id-type="pmid">31687072</pub-id>
</mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Q. G.</given-names></name></person-group> (<year>2011</year>). <article-title>The role of miR-26 in tumors and normal tissues (Review)</article-title>. <source>Oncol. Lett.</source>
<volume>2</volume>, <fpage>1019</fpage>&#x02013;<lpage>1023</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2011.413</pub-id>
<pub-id pub-id-type="pmid">22848262</pub-id>
</mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Girmatsion</surname><given-names>Z.</given-names></name><name><surname>Biliczki</surname><given-names>P.</given-names></name><name><surname>Bonauer</surname><given-names>A.</given-names></name><name><surname>Wimmer-Greinecker</surname><given-names>G.</given-names></name><name><surname>Scherer</surname><given-names>M.</given-names></name><name><surname>Moritz</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Changes in microRNA-1 expression and Ik1 up-regulation in human atrial fibrillation</article-title>. <source>Hear. Rhythm.</source>
<volume>6</volume>, <fpage>1802</fpage>&#x02013;<lpage>1809</lpage>. <pub-id pub-id-type="doi">10.1016/j.hrthm.2009.08.035</pub-id>
</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harling</surname><given-names>L.</given-names></name><name><surname>Lambert</surname><given-names>J.</given-names></name><name><surname>Ashrafian</surname><given-names>H.</given-names></name><name><surname>Darzi</surname><given-names>A.</given-names></name><name><surname>Gooderham</surname><given-names>N. J.</given-names></name><name><surname>Athanasiou</surname><given-names>T.</given-names></name></person-group> (<year>2017</year>). <article-title>Elevated serum microRNA 483-5p levels may predict patients at risk of post-operative atrial fibrillation</article-title>. <source>Eur. J. Cardio-thoracic Surg.</source>
<volume>51</volume>, <fpage>73</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1093/ejcts/ezw245</pub-id>
</mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horita</surname><given-names>M.</given-names></name><name><surname>Farquharson</surname><given-names>C.</given-names></name><name><surname>Stephen</surname><given-names>L. A.</given-names></name></person-group> (<year>2021</year>). <article-title>The role of miR-29 family in disease</article-title>. <source>J. Cell. Biochem.</source>
<volume>122</volume>, <fpage>696</fpage>&#x02013;<lpage>715</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.29896</pub-id>
<pub-id pub-id-type="pmid">33529442</pub-id>
</mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hua</surname><given-names>Y. T.</given-names></name><name><surname>Xu</surname><given-names>W. X.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Xia</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Emerging roles of MiR-133a in human cancers</article-title>. <source>J. Cancer</source>
<volume>12</volume>, <fpage>198</fpage>&#x02013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.7150/JCA.48769</pub-id>
<pub-id pub-id-type="pmid">33391416</pub-id>
</mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Liang</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name></person-group> (<year>2022</year>). <article-title>Upregulated miR-328-3p and its high risk in atrial fibrillation: a systematic review and meta-analysis with meta-regression</article-title>. <source>Med. Baltim.</source>
<volume>101</volume>, <fpage>e28980</fpage>. <pub-id pub-id-type="doi">10.1097/md.0000000000028980</pub-id>
</mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ishida</surname><given-names>M.</given-names></name><name><surname>Selaru</surname><given-names>F. M.</given-names></name></person-group> (<year>2013</year>). <article-title>miRNA-based therapeutic strategies</article-title>. <source>Curr. Pathobiol. Rep.</source>
<volume>1</volume>, <fpage>63</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1007/s40139-012-0004-5</pub-id>
</mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ishizaki</surname><given-names>T.</given-names></name><name><surname>Tamiya</surname><given-names>T.</given-names></name><name><surname>Taniguchi</surname><given-names>K.</given-names></name><name><surname>Morita</surname><given-names>R.</given-names></name><name><surname>Kato</surname><given-names>R.</given-names></name><name><surname>Okamoto</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>miR126 positively regulates mast cell proliferation and cytokine production through suppressing Spred1</article-title>. <source>Genes. Cells</source>
<volume>16</volume>, <fpage>803</fpage>&#x02013;<lpage>814</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2443.2011.01529.x</pub-id>
<pub-id pub-id-type="pmid">21668589</pub-id>
</mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jia</surname><given-names>H.</given-names></name><name><surname>Qu</surname><given-names>M.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>miR-499-5p suppresses C-reactive protein and provides neuroprotection in hypoxic-ischemic encephalopathy in neonatal rat</article-title>. <source>Neurosci. Res.</source>
<volume>161</volume>, <fpage>44</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.neures.2019.12.002</pub-id>
<pub-id pub-id-type="pmid">31812653</pub-id>
</mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jia</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>MicroRNA-1 accelerates the shortening of atrial effective refractory period by regulating KCNE1 and KCNB2 expression: an atrial tachypacing rabbit model</article-title>. <source>PLoS One</source>
<volume>8</volume>, <fpage>856399</fpage>&#x02013;<lpage>e85711</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0085639</pub-id>
</mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kornej</surname><given-names>J.</given-names></name><name><surname>B&#x000f6;rschel</surname><given-names>C. S.</given-names></name><name><surname>B&#x000f6;rschel</surname><given-names>C. S.</given-names></name><name><surname>Benjamin</surname><given-names>E. J.</given-names></name><name><surname>Benjamin</surname><given-names>E. J.</given-names></name><name><surname>Schnabel</surname><given-names>R. B.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights</article-title>. <source>Circ. Res.</source>
<volume>127</volume>, <fpage>4</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.316340</pub-id>
<pub-id pub-id-type="pmid">32716709</pub-id>
</mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lhamyani</surname><given-names>S.</given-names></name><name><surname>Gentile</surname><given-names>A. M.</given-names></name><name><surname>Gir&#x000e1;ldez-P&#x000e9;rez</surname><given-names>R. M.</given-names></name><name><surname>Feij&#x000f3;o-Cuaresma</surname><given-names>M.</given-names></name><name><surname>Romero-Zerbo</surname><given-names>S. Y.</given-names></name><name><surname>Clemente-Postigo</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>miR-21 mimic blocks obesity in mice: a novel therapeutic option</article-title>. <source>Mol. Ther. - Nucleic Acids.</source>
<volume>26</volume>, <fpage>401</fpage>&#x02013;<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1016/j.omtn.2021.06.019</pub-id>
<pub-id pub-id-type="pmid">34552821</pub-id>
</mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Expression of miR-133 and miR-30 in chronic atrial fibrillation in canines</article-title>. <source>Mol. Med. Rep.</source>
<volume>5</volume>, <fpage>1457</fpage>&#x02013;<lpage>1460</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2012.831</pub-id>
<pub-id pub-id-type="pmid">22407060</pub-id>
</mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>MicroRNA-1 in cardiac diseases and cancers</article-title>. <source>Korean J. Physiol. Pharmacol.</source>
<volume>18</volume>, <fpage>359</fpage>&#x02013;<lpage>363</lpage>. <pub-id pub-id-type="doi">10.4196/kjpp.2014.18.5.359</pub-id>
<pub-id pub-id-type="pmid">25352753</pub-id>
</mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Y. D.</given-names></name><name><surname>Hong</surname><given-names>Y. F.</given-names></name><name><surname>Yusufuaji</surname><given-names>Y.</given-names></name><name><surname>Tang</surname><given-names>B. P.</given-names></name><name><surname>Zhou</surname><given-names>X. H.</given-names></name><name><surname>Xu</surname><given-names>G. J.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Altered expression of hyperpolarization-activated cyclic nucleotide-gated channels and microRNA-1 and -133 in patients with age-associated atrial fibrillation</article-title>. <source>Mol. Med. Rep.</source>
<volume>12</volume>, <fpage>3243</fpage>&#x02013;<lpage>3248</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2015.3831</pub-id>
<pub-id pub-id-type="pmid">26005035</pub-id>
</mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ling</surname><given-names>T. Y.</given-names></name><name><surname>Wang</surname><given-names>X. L.</given-names></name><name><surname>Chai</surname><given-names>Q.</given-names></name><name><surname>Lu</surname><given-names>T.</given-names></name><name><surname>Stulak</surname><given-names>J. M.</given-names></name><name><surname>Joyce</surname><given-names>L. D.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Regulation of cardiac CACNB2 by microRNA-499: potential role in atrial fibrillation</article-title>. <source>BBA Clin.</source>
<volume>7</volume>, <fpage>78</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbacli.2017.02.002</pub-id>
<pub-id pub-id-type="pmid">28239561</pub-id>
</mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Friggeri</surname><given-names>A.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Milosevic</surname><given-names>J.</given-names></name><name><surname>Ding</surname><given-names>Q.</given-names></name><name><surname>Thannickal</surname><given-names>V. J.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis</article-title>. <source>J. Exp. Med.</source>
<volume>207</volume>, <fpage>1589</fpage>&#x02013;<lpage>1597</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20100035</pub-id>
<pub-id pub-id-type="pmid">20643828</pub-id>
</mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Pan</surname><given-names>Z.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation</article-title>. <source>Circulation</source>
<volume>122</volume>, <fpage>2378</fpage>&#x02013;<lpage>2387</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.958967</pub-id>
<pub-id pub-id-type="pmid">21098446</pub-id>
</mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Pan</surname><given-names>Z.</given-names></name><name><surname>Shan</surname><given-names>H.</given-names></name><name><surname>Xiao</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation</article-title>. <source>J. Clin. Invest.</source>
<volume>123</volume>, <fpage>1939</fpage>&#x02013;<lpage>1951</lpage>. <pub-id pub-id-type="doi">10.1172/JCI62185</pub-id>
<pub-id pub-id-type="pmid">23543060</pub-id>
</mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lv</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>P.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>T.</given-names></name></person-group> (<year>2021</year>). <article-title>Overexpression of MiR-29b-3p inhibits atrial remodeling in rats by targeting PDGF-B signaling pathway</article-title>. <source>Oxid. Med. Cell. Longev.</source>
<volume>2021</volume>, <fpage>3763529</fpage>. <pub-id pub-id-type="doi">10.1155/2021/3763529</pub-id>
<pub-id pub-id-type="pmid">33520084</pub-id>
</mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ma</surname><given-names>Q.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Duan</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Circulating miR-1 as a potential predictor of left ventricular remodeling following acute ST-segment myocardial infarction using cardiac magnetic resonance</article-title>. <source>Quant. Imaging Med. Surg.</source>
<volume>10</volume>, <fpage>1490</fpage>&#x02013;<lpage>1503</lpage>. <pub-id pub-id-type="doi">10.21037/QIMS-19-829</pub-id>
<pub-id pub-id-type="pmid">32676367</pub-id>
</mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ma</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>MiR-499 is a diagnostic biomarker of paroxysmal atrial fibrillation involved in the development of atrial fibrillation</article-title>. <source>Int. J. Clin. Exp. Pathology</source>
<volume>10</volume>, <fpage>4221</fpage>&#x02013;<lpage>4231</lpage>.</mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Malpeli</surname><given-names>G.</given-names></name><name><surname>Barbi</surname><given-names>S.</given-names></name><name><surname>Tosadori</surname><given-names>G.</given-names></name><name><surname>Greco</surname><given-names>C.</given-names></name><name><surname>Zupo</surname><given-names>S.</given-names></name><name><surname>Pedron</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways</article-title>. <source>Oncotarget</source>
<volume>9</volume>, <fpage>29753</fpage>&#x02013;<lpage>29771</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.25707</pub-id>
<pub-id pub-id-type="pmid">30038718</pub-id>
</mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matson</surname><given-names>K.</given-names></name><name><surname>Macleod</surname><given-names>A.</given-names></name><name><surname>Mehta</surname><given-names>N.</given-names></name><name><surname>Sempek</surname><given-names>E.</given-names></name><name><surname>Tang</surname><given-names>X.</given-names></name></person-group> (<year>2023</year>). <article-title>Impacts of MicroRNA-483 on human diseases</article-title>. <source>Non-coding RNA</source>
<volume>9</volume>, <fpage>37</fpage>. <pub-id pub-id-type="doi">10.3390/ncrna9040037</pub-id>
<pub-id pub-id-type="pmid">37489457</pub-id>
</mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McManus</surname><given-names>D. D.</given-names></name><name><surname>Lin</surname><given-names>H.</given-names></name><name><surname>Tanriverdi</surname><given-names>K.</given-names></name><name><surname>Quercio</surname><given-names>M.</given-names></name><name><surname>Yin</surname><given-names>X.</given-names></name><name><surname>Larson</surname><given-names>M. G.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Relations between circulating microRNAs and atrial fibrillation: data from the framingham offspring study</article-title>. <source>Hear. Rhythm</source>
<volume>11</volume>, <fpage>663</fpage>&#x02013;<lpage>669</lpage>. <pub-id pub-id-type="doi">10.1016/j.hrthm.2014.01.018</pub-id>
</mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morishima</surname><given-names>M.</given-names></name><name><surname>Iwata</surname><given-names>E.</given-names></name><name><surname>Nakada</surname><given-names>C.</given-names></name><name><surname>Tsukamoto</surname><given-names>Y.</given-names></name><name><surname>Takanari</surname><given-names>H.</given-names></name><name><surname>Miyamoto</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Atrial fibrillation-mediated upregulation of miR-30d regulates myocardial electrical remodeling of the G-protein-gated K(+) channel, Ik.ACh</article-title>. <source>IK.ACh. Circ. J.</source>
<volume>80</volume>, <fpage>1346</fpage>&#x02013;<lpage>1355</lpage>. <pub-id pub-id-type="doi">10.1253/circj.CJ-15-1276</pub-id>
<pub-id pub-id-type="pmid">27180889</pub-id>
</mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nishi</surname><given-names>H.</given-names></name><name><surname>Sakaguchi</surname><given-names>T.</given-names></name><name><surname>Miyagawa</surname><given-names>S.</given-names></name><name><surname>Yoshikawa</surname><given-names>Y.</given-names></name><name><surname>Fukushima</surname><given-names>S.</given-names></name><name><surname>Saito</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Impact of microRNA expression in human atrial tissue in patients with atrial fibrillation undergoing cardiac surgery</article-title>. <source>PLoS One</source>
<volume>8</volume>, <fpage>e73397</fpage>&#x02013;<lpage>e73398</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0073397</pub-id>
<pub-id pub-id-type="pmid">24069193</pub-id>
</mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olivia</surname><given-names>L. H.</given-names></name><name><surname>Khurshid</surname><given-names>S.</given-names></name><name><surname>Weng</surname><given-names>L. C.</given-names></name><name><surname>Anderson</surname><given-names>C. D.</given-names></name><name><surname>Wang</surname><given-names>E. Y.</given-names></name><name><surname>Ashburner</surname><given-names>J. M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Development and validation of a prediction model for atrial fibrillation using electronic health records</article-title>. <source>JACC Clin. Electrophysiol.</source>
<volume>5</volume>, <fpage>1331</fpage>&#x02013;<lpage>1341</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacep.2019.07.016</pub-id>
<pub-id pub-id-type="pmid">31753441</pub-id>
</mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paul</surname><given-names>A.</given-names></name><name><surname>Pai</surname><given-names>P. G.</given-names></name><name><surname>Ariyannur</surname><given-names>P. S.</given-names></name><name><surname>Joy</surname><given-names>R. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Diagnostic accuracy of MicroRNA 208b level with respect to different types of atrial fibrillation</article-title>. <source>Indian Heart J.</source>
<volume>73</volume>, <fpage>506</fpage>&#x02013;<lpage>510</lpage>. <pub-id pub-id-type="doi">10.1016/j.ihj.2021.06.018</pub-id>
<pub-id pub-id-type="pmid">34474768</pub-id>
</mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reilly</surname><given-names>S. N.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Carnicer</surname><given-names>R.</given-names></name><name><surname>Recalde</surname><given-names>A.</given-names></name><name><surname>Muszkiewicz</surname><given-names>A.</given-names></name><name><surname>Jayaram</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Up-regulation of MIR-31 in human atrial fibrillation begets the arrhythmia by depleting dystrophin and neuronal nitric oxide synthase</article-title>. <source>Sci. Transl. Med.</source>
<volume>8</volume>, <fpage>340ra74</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aac4296</pub-id>
</mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rivera-Caravaca</surname><given-names>J. M.</given-names></name><name><surname>Teruel-Montoya</surname><given-names>R.</given-names></name><name><surname>Rold&#x000e1;n</surname><given-names>V.</given-names></name><name><surname>Cifuentes-Riquelme</surname><given-names>R.</given-names></name><name><surname>Crespo-Matas</surname><given-names>J. A.</given-names></name><name><surname>de los Reyes-Garc&#x000ed;a</surname><given-names>A. M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Pilot study on the role of circulating mirnas for the improvement of the predictive ability of the 2mace score in patients with atrial fibrillation</article-title>. <source>J. Clin. Med.</source>
<volume>9</volume>, <fpage>3645</fpage>&#x02013;<lpage>3711</lpage>. <pub-id pub-id-type="doi">10.3390/jcm9113645</pub-id>
<pub-id pub-id-type="pmid">33198388</pub-id>
</mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scridon</surname><given-names>A.</given-names></name><name><surname>Balan</surname><given-names>A. I.</given-names></name><name><surname>Halatiu</surname><given-names>V. B.</given-names></name><name><surname>Cozac</surname><given-names>D. A.</given-names></name><name><surname>Bobarnac</surname><given-names>R. L.</given-names></name><name><surname>Moldovan</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>miR-328 - a novel diagnostic and predictive atrial fibrillation biomarker in spontaneously hypertensive rats</article-title>. <source>Europace</source>
<volume>25</volume>, <fpage>2023</fpage>. <pub-id pub-id-type="doi">10.1093/europace/euad122.576</pub-id>
</mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scridon</surname><given-names>A.</given-names></name><name><surname>&#x0015e;erban</surname><given-names>R. C.</given-names></name><name><surname>Chevalier</surname><given-names>P.</given-names></name></person-group> (<year>2018</year>). <article-title>Atrial fibrillation: neurogenic or myogenic?</article-title>
<source>Arch. Cardiovasc. Dis.</source>
<volume>111</volume>, <fpage>59</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.acvd.2017.11.001</pub-id>
<pub-id pub-id-type="pmid">29229215</pub-id>
</mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>&#x00218;erban</surname><given-names>R. C.</given-names></name><name><surname>Balan</surname><given-names>A. I.</given-names></name><name><surname>Perian</surname><given-names>M.</given-names></name><name><surname>Pintilie</surname><given-names>I.</given-names></name><name><surname>Somkereki</surname><given-names>C.</given-names></name><name><surname>Hu&#x0021b;anu</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Atrial electrical remodeling induced by chronic ischemia and inflammation in patients with stable coronary artery disease</article-title>. <source>Chin. J. Physiol.</source>
<volume>62</volume>, <fpage>11</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.4103/CJP.CJP_2_19</pub-id>
<pub-id pub-id-type="pmid">30942194</pub-id>
</mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shan</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Pan</surname><given-names>Z.</given-names></name><name><surname>Cai</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines</article-title>. <source>Cardiovasc. Res.</source>
<volume>83</volume>, <fpage>465</fpage>&#x02013;<lpage>472</lpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvp130</pub-id>
<pub-id pub-id-type="pmid">19398468</pub-id>
</mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soeki</surname><given-names>T.</given-names></name><name><surname>Matsuura</surname><given-names>T.</given-names></name><name><surname>Bando</surname><given-names>S.</given-names></name><name><surname>Tobiume</surname><given-names>T.</given-names></name><name><surname>Uematsu</surname><given-names>E.</given-names></name><name><surname>Ise</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Relationship between local production of microRNA-328 and atrial substrate remodeling in atrial fibrillation</article-title>. <source>J. Cardiol.</source>
<volume>68</volume>, <fpage>472</fpage>&#x02013;<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1016/j.jjcc.2015.12.007</pub-id>
<pub-id pub-id-type="pmid">26987792</pub-id>
</mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sugiyama</surname><given-names>Y.</given-names></name><name><surname>Yoshimi</surname><given-names>R.</given-names></name><name><surname>Takeno</surname><given-names>M.</given-names></name><name><surname>Kunishita</surname><given-names>Y.</given-names></name><name><surname>Kishimoto</surname><given-names>D.</given-names></name><name><surname>Kamiyama</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>miR-1 is a novel biomarker for polymyositis/dermatomyositis-associated interstitial lung disease</article-title>. <source>Mod. Rheumatol.</source>
<volume>30</volume>, <fpage>878</fpage>&#x02013;<lpage>883</lpage>. <pub-id pub-id-type="doi">10.1080/14397595.2019.1661584</pub-id>
<pub-id pub-id-type="pmid">31483179</pub-id>
</mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>R. U.</given-names></name><name><surname>Prieto-Vila</surname><given-names>M.</given-names></name><name><surname>Hironaka</surname><given-names>A.</given-names></name><name><surname>Ochiya</surname><given-names>T.</given-names></name></person-group> (<year>2017</year>). <article-title>The role of extracellular vesicle microRNAs in cancer biology</article-title>. <source>Clin. Chem. Lab. Med.</source>
<volume>55</volume>, <fpage>648</fpage>&#x02013;<lpage>656</lpage>. <pub-id pub-id-type="doi">10.1515/cclm-2016-0708</pub-id>
<pub-id pub-id-type="pmid">28231055</pub-id>
</mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Terentyev</surname><given-names>D.</given-names></name><name><surname>Belevych</surname><given-names>A. E.</given-names></name><name><surname>Terentyeva</surname><given-names>R. M. M. M.</given-names></name><name><surname>Malana</surname><given-names>G. E.</given-names></name><name><surname>Kuhn</surname><given-names>D. E.</given-names></name><name><surname>Abdellatif</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2</article-title>. <source>Circ. Res.</source>
<volume>104</volume>, <fpage>514</fpage>&#x02013;<lpage>521</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.181651</pub-id>
<pub-id pub-id-type="pmid">19131648</pub-id>
</mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thum</surname><given-names>T.</given-names></name><name><surname>Gross</surname><given-names>C.</given-names></name><name><surname>Fiedler</surname><given-names>J.</given-names></name><name><surname>Fischer</surname><given-names>T.</given-names></name><name><surname>Kissler</surname><given-names>S.</given-names></name><name><surname>Bussen</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts</article-title>. <source>Nature</source>
<volume>456</volume>, <fpage>980</fpage>&#x02013;<lpage>984</lpage>. <pub-id pub-id-type="doi">10.1038/nature07511</pub-id>
<pub-id pub-id-type="pmid">19043405</pub-id>
</mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tran</surname><given-names>K. V.</given-names></name><name><surname>Majka</surname><given-names>J.</given-names></name><name><surname>Sanghai</surname><given-names>S.</given-names></name><name><surname>Sardana</surname><given-names>M.</given-names></name><name><surname>Lessard</surname><given-names>D.</given-names></name><name><surname>Milstone</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Micro-RNAs are related to epicardial adipose tissue in participants with atrial fibrillation: data from the MiRhythm study</article-title>. <source>Front. Cardiovasc. Med.</source>
<volume>6</volume>, <fpage>115</fpage>&#x02013;<lpage>118</lpage>. <pub-id pub-id-type="doi">10.3389/fcvm.2019.00115</pub-id>
<pub-id pub-id-type="pmid">31475159</pub-id>
</mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsoporis</surname><given-names>J. N.</given-names></name><name><surname>Fazio</surname><given-names>A.</given-names></name><name><surname>Rizos</surname><given-names>I. K.</given-names></name><name><surname>Izhar</surname><given-names>S.</given-names></name><name><surname>Proteau</surname><given-names>G.</given-names></name><name><surname>Salpeas</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Increased right atrial appendage apoptosis is associated with differential regulation of candidate MicroRNAs 1 and 133A in patients who developed atrial fibrillation after cardiac surgery</article-title>. <source>J. Mol. Cell. Cardiol.</source>
<volume>121</volume>, <fpage>25</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2018.06.005</pub-id>
<pub-id pub-id-type="pmid">29885959</pub-id>
</mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van Rooij</surname><given-names>E.</given-names></name><name><surname>Sutherland</surname><given-names>L. B.</given-names></name><name><surname>Thatcher</surname><given-names>J. E.</given-names></name><name><surname>DiMaio</surname><given-names>J. M.</given-names></name><name><surname>Naseem</surname><given-names>R. H.</given-names></name><name><surname>Marshall</surname><given-names>W. S.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<volume>105</volume>, <fpage>13027</fpage>&#x02013;<lpage>13032</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0805038105</pub-id>
<pub-id pub-id-type="pmid">18723672</pub-id>
</mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Ye</surname><given-names>Q.</given-names></name><name><surname>Bai</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Inhibiting microRNA-155 attenuates atrial fibrillation by targeting CACNA1C</article-title>. <source>J. Mol. Cell. Cardiol.</source>
<volume>155</volume>, <fpage>58</fpage>&#x02013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2021.02.008</pub-id>
<pub-id pub-id-type="pmid">33636223</pub-id>
</mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Ding</surname><given-names>W.</given-names></name><name><surname>Cai</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name></person-group> (<year>2019a</year>). <article-title>Ablation alleviates atrial fibrillation by regulating the signaling pathways of endothelial nitric oxide synthase/nitric oxide via miR-155-5p and miR-24-3p</article-title>. <source>J. Cell. Biochem.</source>
<volume>120</volume>, <fpage>4451</fpage>&#x02013;<lpage>4462</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.27733</pub-id>
<pub-id pub-id-type="pmid">30302809</pub-id>
</mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Gao</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Yao</surname><given-names>H. C.</given-names></name></person-group> (<year>2019b</year>). <article-title>Plasma miR-208b and miR-499: potential biomarkers for severity of coronary artery disease</article-title>. <source>Dis. Markers</source>
<volume>2019</volume>, <fpage>9842427</fpage>. <pub-id pub-id-type="doi">10.1155/2019/9842427</pub-id>
<pub-id pub-id-type="pmid">31885748</pub-id>
</mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Xie</surname><given-names>W.</given-names></name><name><surname>Guan</surname><given-names>H.</given-names></name></person-group> (<year>2023</year>). <article-title>The diagnostic, prognostic role and molecular mechanism of miR-328 in human cancer</article-title>. <source>Biomed. Pharmacother.</source>
<volume>157</volume>, <fpage>114031</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2022.114031</pub-id>
<pub-id pub-id-type="pmid">36413837</pub-id>
</mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>X. J.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>F. Y.</given-names></name><name><surname>Wei</surname><given-names>G. C.</given-names></name><name><surname>Liang</surname><given-names>Z. G.</given-names></name><name><surname>Yao</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Biological significance of miR-126 expression in atrial fibrillation and heart failure</article-title>. <source>Braz. J. Med. Biol. Res.</source>
<volume>48</volume>, <fpage>983</fpage>&#x02013;<lpage>989</lpage>. <pub-id pub-id-type="doi">10.1590/1414-431X20154590</pub-id>
<pub-id pub-id-type="pmid">26313139</pub-id>
</mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wiedmann</surname><given-names>F.</given-names></name><name><surname>Kraft</surname><given-names>M.</given-names></name><name><surname>Kallenberger</surname><given-names>S.</given-names></name><name><surname>B&#x000fc;scher</surname><given-names>A.</given-names></name><name><surname>Paasche</surname><given-names>A.</given-names></name><name><surname>Blochberger</surname><given-names>P. L.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>MicroRNAs regulate TASK-1 and are linked to myocardial dilatation in atrial fibrillation</article-title>. <source>J. Am. Heart Assoc.</source>
<volume>11</volume>, <fpage>e023472</fpage>. <pub-id pub-id-type="doi">10.1161/JAHA.121.023472</pub-id>
<pub-id pub-id-type="pmid">35301863</pub-id>
</mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Gao</surname><given-names>B.</given-names></name><name><surname>Shen</surname><given-names>M.</given-names></name><name><surname>Wei</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Zhuang</surname><given-names>W.</given-names></name></person-group> (<year>2023</year>). <article-title>lncRNA LENGA sponges miR-378 to promote myocardial fibrosis in atrial fibrillation</article-title>. <source>Open Med.</source>
<volume>18</volume>, <fpage>20230831</fpage>. <pub-id pub-id-type="doi">10.1515/med-2023-0831</pub-id>
</mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xinyuan</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Yong</surname><given-names>Z.</given-names></name><name><surname>Xueting Zhang</surname><given-names>X. W.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name></person-group> (<year>2022</year>). <article-title>miR-29b ameliorates atrial fibrosis in rats with atrial fibrillation by targeting TGF&#x003b2;R&#x00399; and inhibiting the activation of Smad-2/3 pathway</article-title>. <source>J. Bioenerg. Biomembr.</source>
<volume>54</volume>, <fpage>81</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1007/s10863-022-09934-7</pub-id>
<pub-id pub-id-type="pmid">35322290</pub-id>
</mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Jing</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zha</surname><given-names>X.</given-names></name><name><surname>Zeng</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia</article-title>. <source>Exp. Hematol. Oncol.</source>
<volume>3</volume>, <fpage>17</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1186/2162-3619-3-17</pub-id>
<pub-id pub-id-type="pmid">25006537</pub-id>
</mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yan</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>Aberrant expression of miR-21 in patients with inflammatory bowel disease: a protocol for systematic review and meta analysis</article-title>. <source>Med. Baltim.</source>
<volume>99</volume>, <fpage>e19693</fpage>. <pub-id pub-id-type="doi">10.1097/MD.0000000000019693</pub-id>
</mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Lin</surname><given-names>H.</given-names></name><name><surname>Xiao</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2</article-title>. <source>Nat. Med.</source>
<volume>13</volume>, <fpage>486</fpage>&#x02013;<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1038/nm1569</pub-id>
<pub-id pub-id-type="pmid">17401374</pub-id>
</mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yao</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>You</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Xie</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>LncRNA MIAT/miR-133a-3p axis regulates atrial fibrillation and atrial fibrillation-induced myocardial fibrosis</article-title>. <source>Mol. Biol. Rep.</source>
<volume>47</volume>, <fpage>2605</fpage>&#x02013;<lpage>2617</lpage>. <pub-id pub-id-type="doi">10.1007/s11033-020-05347-0</pub-id>
<pub-id pub-id-type="pmid">32130618</pub-id>
</mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yuan</surname><given-names>C. T.</given-names></name><name><surname>Li</surname><given-names>X. X.</given-names></name><name><surname>Cheng</surname><given-names>Q. J.</given-names></name><name><surname>Wang</surname><given-names>Y. H.</given-names></name><name><surname>Wang</surname><given-names>J. H.</given-names></name><name><surname>Liu</surname><given-names>C. L.</given-names></name></person-group> (<year>2015</year>). <article-title>MiR-30a regulates the atrial fibrillation-induced myocardial fibrosis by targeting snail 1</article-title>. <source>Int. J. Clin. Exp. Pathol.</source>
<volume>8</volume>, <fpage>15527</fpage>&#x02013;<lpage>15536</lpage>.<pub-id pub-id-type="pmid">26884822</pub-id>
</mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Yan</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>He</surname><given-names>M.</given-names></name><name><surname>Lei</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Micro RNA-483 amelioration of experimental pulmonary hypertension</article-title>. <source>EMBO Mol. Med.</source>
<volume>12</volume>, <fpage>e11303</fpage>&#x02013;<lpage>e11313</lpage>. <pub-id pub-id-type="doi">10.15252/emmm.201911303</pub-id>
<pub-id pub-id-type="pmid">32324970</pub-id>
</mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Doxycycline attenuates atrial remodeling by interfering with microRNA-21 and downstream phosphatase and tensin homolog (PTEN)/phosphoinositide 3-kinase (PI3K) signaling pathway</article-title>. <source>Med. Sci. Monit.</source>
<volume>24</volume>, <fpage>5580</fpage>&#x02013;<lpage>5587</lpage>. <pub-id pub-id-type="doi">10.12659/MSM.909800</pub-id>
<pub-id pub-id-type="pmid">30098136</pub-id>
</mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Xiao-Ping</surname><given-names>X.</given-names></name><name><surname>Xu-Ai</surname><given-names>R.</given-names></name><name><surname>Cui</surname><given-names>T.</given-names></name></person-group> (<year>2019</year>). <article-title>Plasma miRNA-155 levels predict atrial fibrillation recurrence after cardioversion</article-title>. <source>Heart Surg. Forum</source>
<volume>22</volume>, <fpage>E140</fpage>&#x02013;<lpage>E148</lpage>. <pub-id pub-id-type="doi">10.1532/hsf.2281</pub-id>
<pub-id pub-id-type="pmid">31013225</pub-id>
</mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Geng</surname><given-names>Y.</given-names></name><name><surname>Xue</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>MicroRNA profiling of atrial fibrillation in canines: MiR-206 modulates intrinsic cardiac autonomic nerve remodeling by regulating SOD1</article-title>. <source>PLoS One</source>
<volume>10</volume>, <fpage>01226744</fpage>&#x02013;<lpage>e122716</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0122674</pub-id>
</mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Maleck</surname><given-names>C.</given-names></name><name><surname>Von Ungern-Sternberg</surname><given-names>S. N. I.</given-names></name><name><surname>Neupane</surname><given-names>B.</given-names></name><name><surname>Heinzmann</surname><given-names>D.</given-names></name><name><surname>Marquardt</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Circulating MicroRNA-21 correlates with left atrial low-voltage areas and is associated with procedure outcome in patients undergoing atrial fibrillation ablation</article-title>. <source>Circ. Arrhythmia Electrophysiol.</source>
<volume>11</volume>, <fpage>1</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCEP.118.006242</pub-id>
</mixed-citation></ref></ref-list></back></article>